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ABSTRACT 
Obstructive sleep apnea (OSA) is a significant risk factor for developing atrial 
fibrillation (AF) in clinical populations, but the underlying mechanisms are unknown. 
Intermittent hypoxia (IH), as elicited by nocturnal airway obstructive events in OSA 
patients, has been implicated as the mediator of OSA-related cardiovascular 
outcomes. However, the role of IH in OSA-related atrial arrhythmogenesis has not 
been reported. For the first time, this thesis demonstrates AF promotion in a rodent 
model of OSA using IH to mimic hypoxic events, and investigates the underlying 
vulnerable substrates of induced AF. Rats exposed to IH for 7 days had significantly 
enhanced AF vulnerability compared to control animals exposed to normoxic 
conditions using both programmed electrical stimulation and atrial burst pacing to 
evaluate AF susceptibility. Enhanced AF vulnerability was accompanied by a 
number of atrial substrate changes that have not been reported previously in an IH 
model of OSA, including (1) lowered atrial Cx 43 content, (2) heightened cholinergic 
sensitivity with increased muscarinic receptor protein expression, and (3) alterations 
in adrenergic function characterized by enhanced responses to propranolol and 
blunted responses to isoproterenol. These findings highlight a potential causal role 
for chronic IH in OSA-related AF susceptibility and in the formation of AF-promoting 
vulnerable substrates. 
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1.1 Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and a global 
health burden. The presently available therapeutic options carry considerable risks 
and are not effective for most patients, highlighting the need for new approaches to 
treatment. Rarely a primary electric disorder, AF most often arises as a 
manifestation of a host of predisposing diseases. The development of improved 
treatment modalities is limited by an incomplete appreciation of the mechanisms of 
AF, particularly with respect to its underlying risk factors, although the importance of 
the autonomic nervous system has been demonstrated in a variety of scenarios, 
both clinically and with the use of animal models. In addition to a number of 
conditions classically associated with AF, the common sleep breathing disorder, 
Obstructive Sleep Apnea (OSA), is being increasingly recognized as an important 
AF risk factor, but the underlying mechanisms are not known. Intermittent hypoxia 
(IH) is a critical pathophysiological component of OSA and is used to model the 
disease, primarily in rodents. The use of these models has implicated IH in 
mediating many OSA-related cardiovascular outcomes, but IH has not been used in 
investigations of atrial arrhythmias. IH also causes profound autonomic dysfunction 
found in the human disease which, given the role of the autonomic nervous system 
in predisposing the atria to AF, may be arrhythmogenic in the context of OSA. 
This thesis focuses on the role of IH in predisposing the atria to AF (in vivo) 
through the creation of AF substrates. This first chapter will provide an overview of 
AF, highlighting the role of autonomic influences and connexins in AF 
pathophysiology. This is followed by a description of OSA, emphasizing the role of 
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IH and its effects on the autonomic nervous system and the use of IH models to 
elucidate mechanisms of OSA-related cardiovascular outcomes. 
 
1.2 Atrial fibrillation 
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered by 
the general practitioner (Benjamin et al., 1998). It is characterized by rapid, chaotic 
atrial activation, manifesting as an undulating isoelectric line in place of regular P 
waves on the electrocardiogram (ECG). This is accompanied by an “irregularly 
irregular” QRS pattern (an irregular QRS rhythm with no apparent pattern of 
irregularity, Krummen et al., 2006), as the extremely rapid atrial rates during AF 
exceed the impulse carrying capacity of the atrioventricular node (AVN), resulting in 
uncontrolled ventricular responses related to AVN hysteresis. Initially AF episodes 
are often self-terminating and limited in duration (less than one week), which is 
termed paroxysmal AF, but over time, the episodes can become longer, and AF 
forms will often progress from paroxysmal to persistent (episodes lasting longer than 
1 week and are routinely successfully terminated by cardioversion), or permanent 
(AF is continually present and a strategy of rhythm control is not advisable) (January 
et al., 2014). AF is most often the result of one or more predisposing pathologies, 
and the progression to more advanced forms is often associated with advancement 
of these underlying diseases. The progressive nature of AF is also partially caused 
by AF itself, as rapid rates during AF cause alterations of the atria that favour 
chronicity of the arrhythmia (“AF begets AF”; Wijffels et al., 1996; Morillo et al., 1995; 
Thijssen et al., 2000).  
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1.2.1 Clinical relevance: The global AF burden 
AF is a major health care burden, due to complications and deaths. The 
current evidence suggests that AF affects about 1% of the general population 
(Kannel et al., 1998). However, the prevalence of AF increases with age, affecting 
over 10% of individuals over the age of 75 (Nixon, 2011). The prevalence of AF 
more than doubled from 1993 to 2007 (Piccini et al., 2012), and is expected to 
continue to rise due to the aging of the population (January et al., 2014). In adults 
between the ages of 40 and 55, the lifetime risk for developing AF has been 
estimated to be 22-26% (Heeringa et al., 2006). 
Largely as a risk factor for stroke and heart failure, AF is associated with 
significant morbidity and increases mortality in affected individuals across a wide 
range of ages independent of preexisting conditions (Benjamin et al., 1998). AF is 
the cause of 20-25% of all strokes (Miyasaka et al., 2005) and AF-related strokes 
are nearly twice as likely to be fatal than strokes of other origins (Lin et al., 1996).  
AF also increases the risk of developing heart failure three-fold (Camm et al., 2012) 
and worsens prognosis in patients hospitalized for heart failure (Schotten et al., 
2011).  
In spite of active research efforts, there continues to be a lack of satisfactory 
therapeutic interventions that improve prognosis in AF patients (Nattel et al., 2002b). 
One therapeutic approach is the use of antiarrhythmic drugs that restore and 
maintain sinus rhythm by altering cardiac electrophysiology. However, these drugs 
are not specific for atrial electrophysiology and increase the risk of life-threatening 
ventricular arrhythmias such as Torsade de pointes (Nattel, 1998; January et al., 
2014). Direct current cardioversion (delivery of an electric shock synchronized with 
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the “R wave” of the heart) can also restore sinus rhythm, but AF reoccurrence is 
likely in most patients without attempts to maintain sinus rhythm (January et al., 
2014; Lundstrom and Ryden, 1988). Other non-pharmacological approaches to AF 
treatment include targeted ablation or electrical isolation of arrhythmia generating 
tissue (often the pulmonary veins) and the reduction and fragmentation of atrial 
contiguous surface area (e.g. the MAZE procedure), the later of which is highly 
effective in AF prevention, but is a highly invasive procedure that is not applicable to 
most patients (Nattel et al., 2002b). Ablative therapies are primarily only relevant for 
patients with focal AF and the risk of recurrent AF after a single ablation procedure is 
still 47% in paroxysmal AF patients and 58% in non-paroxysmal AF patients at long-
term follow-up, as highlighted by a recent meta-analysis (Ganesan et al., 2013). 
Thus, AF remains a challenge with respect to its treatment, and a growing problem 
for health care systems due to its growing prevalence, significant mortality and costs 
associated with its adverse outcomes.  
 
1.2.2 Mechanisms of AF 
1.2.2.1 Overview  
AF involves three major processes: initiation of the arrhythmia, arrhythmia 
maintenance and progression toward more severe forms (Heijman et al., 2014). 
Each episode of AF requires a trigger for initiation, together with a vulnerable 
substrate for maintenance of the arrhythmia. In the context of AF, substrates refer to 
the underlying electrical or structural alterations of the atria that support arrhythmia 
vulnerability. Abnormal electrical wavefronts emerging spontaneously from regions 
such as the pulmonary veins are the most common source of AF triggers 
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(Haissaguerre et al., 1998; Jalife et al., 2009). These ectopic atrial foci are thought to 
arise primarily as a result of triggered activity, due to either early afterdepolarizations 
(EAD)s or delayed afterdepolarizations (DAD)s. Either way, the trigger alone cannot 
initiate AF; electrical wavefronts must also propagate through a suitable 
arrhythmogenic substrate characterized by reduced refractoriness, enhanced spatial 
heterogeneity of refractoriness, conduction abnormalities and/or structural 
heterogeneities (Jones et al., 2012; Nattel et al., 2002a), giving rise to re-entry and 
AF maintenance. Functional substrates can occur transiently in structurally normal 
atria, such as in paroxysmal AF or in AF induced in experimental animals (Jalife et 
al., 2009). However, as AF progresses to more severe forms (i.e. from paroxysmal 
to persistent and permanent AF) the atria develop substantially altered substrates 
involving both altered ion channel function and/or expression and irreversible 
structural changes (Iwasaki et al., 2011). This is due in part to atrial remodelling 
induced by AF itself (Thijssen et al., 2000). Once initiated, the rapid rates during AF 
(Nattel 2002a) cause progressive changes in the atria that facilitate maintenance of 
the arrhythmia and re-initiation should it terminate spontaneously or by interventions 
(“AF begets AF”; Wijffels et al., 1995; Morillo et al., 1995).  
There are also a number of factors that promote the initial development of a 
vulnerable substrate necessary for re-entry and AF maintenance. AF is a highly 
heterogeneous condition, occurring most often as a consequence of a wide range of 
predisposing diseases. AF that occurs in the absence of any demonstrable disease 
has been classically called “lone AF” (Rosiak et al., 2010), but increasingly the use 
of the term has been discouraged in clinical practice (January et al., 2014). Although 
once thought to occur in roughly 30% of all AF patients (Wolf et al., 1991; Roy et al., 
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2008), long-term data revealed that lone AF accounts for only 2% of all AF cases 
(Schoonderwoerd et al., 2008; Jahangir et al., 2007; Rosiak et al., 2010). Long-
established AF risk factors that promote substrate vulnerability include hypertension, 
heart failure, valve disease and thyroid disease (January et al., 2014). There are 
also a number of newly emerging risk factors including congenital heart disease, 
predisposing gene variants, and, according to increasing evidence, OSA. Although 
new risk factors for AF continue to be identified, the mechanisms underlying their 
relations to AF are not well understood. One hope is that an improved understanding 
of AF mechanisms and its underlying its risk factors may enable discovery of novel 
AF therapies that target the specific problem in affected individuals.  
The mechanisms of AF are somewhat controversial but it is widely accepted 
that two major pro-arrhythmic mechanisms are involved: triggered activity and re-
entry. In the presence of a vulnerable substrate that is conducive to AF 
maintenance, triggered activity can initiate AF, followed by re-entry maintenance, or 
maintain AF as a driver when arising from an ectopic focus firing rapidly and 
repetitively. Alternatively, AF can be maintained by re-entry, in the form of a single 
localized re-entry circuit or multiple functional re-entry circuits. In multiple circuit re-
entry, the irregular atrial activity that defines AF is a direct consequence of the 
primary arrhythmia mechanism. In AF driven by ectopic foci or a single re-entry 
circuit, irregular atrial activity is thought to be due to fibrillatory conduction of 
wavefronts spawned from the primary arrhythmia generator (the ectopic focus or 
primary re-entry circuit) due to spatially variable refractory properties of atrial tissue. 
The following sections will describe the mechanisms underlying triggered activity 
and re-entry, with specific emphasis on the relationships between basic arrhythmia 
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mechanisms, the initiation and maintenance of AF and the autonomic nervous 
system.  
 
1.2.2.2 Triggered activity and AF initiation 
Ectopic atrial foci that participate in the initiation and maintenance of AF are 
thought to be primarily due to triggered activity (Andrade et al., 2014). Triggered 
activity arises from depolarizing membrane potential oscillations that occur during or 
after normal action potentials, called afterdepolarizations. Afterdepolarizations that 
are large enough to reach threshold trigger new action potentials, which can in turn 
elicit more action potentials, resulting in self-sustaining runs of triggered activity. 
Depending on the phase of the action potential in which they occur, 
afterdepolarizations are classified as either “early afterdepolarizations” (EADs) or 
“delayed afterdepolarizations” (DADs). DADs are membrane potential oscillations 
that occur following repolarization of the action potential (phase 4) while EADs occur 
during the action potential plateau (phase 2) or during the late phase 3 
repolarization. DADs are the most common contributors to focal ectopic activity in 
the atria (Heijman et al., 2012) and are favoured by conditions that promote 
intracellular calcium overload, such as β-adrenergic stimulation, hypertrophy and 
ischemia (Jalife et al., 2009). Excess diastolic calcium is handled primarily by the 
sodium calcium exchanger (NCX), which extrudes 1 calcium ion for 3 sodium ions, 
causing a net depolarizing current, the transient inward current, which underlies 
DADs (Heijman et al., 2014; Wakili et al., 2011). \ 
EADs are favoured by conditions promoting action potential duration (APD) 
prolongation, such as with a loss of repolarizing outward K+ currents or an increase 
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of inward currents (Jalife et al., 2009). The inward current most likely responsible for 
the generation of EADs is the calcium window current (Jalife et al., 2009). These 
currents occur when sufficient time has passed for the L-type calcium current (ICaL) 
to recover from inactivation (such as during prolonged action potentials). As a result, 
any abnormal depolarizing current can activate L-type calcium channels from a 
closed state (Schotten et al., 2011; January and Riddle, 1989), resulting in a 
transient inward current that can lead to EADs.  
 
1.2.2.3 Mechanisms of AF maintenance and re-entry 
Re-entry arises when an electrical impulse persistently reactivates an area of 
tissue, often due to circular conduction around a circuit (circus movement re-entry). 
Re-entry circuits may form around fixed anatomic obstacles, such as those formed 
by the venae cavae, pulmonary veins or a region of inexcitability caused by scar 
tissue. Re-entry requires initiation by a trigger, often in the form of a premature 
ectopic beat, and depends on the occurrence of unidirectional block so that 
activation only occurs in one direction within the circuit (Jalife et al., 2009). Re-entry 
also requires that the conduction time around the circuit is longer than the refractory 
period to permit the recovery of excitability within the circuit. Therefore, a relatively 
long circuit, short RP and slow conduction velocity of the impulse make re-entry 
more likely. In other words, the wavelength (equal to the refractory period x 
conduction velocity) must be shorter than the path length of the circuit (Jalife et al., 
2009). If the wavelength is greater than the length of a potential circuit, the impulse 
will traverse the circuit in a time shorter than the refractory period, forcing it to 
encounter its refractory tail and be extinguished (Nattel, 2002).  
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Re-entry occurring in the absence of a fixed anatomical substrate is termed 
functional re-entry, when a premature impulse encounters localized refractoriness 
and re-enters around this functional barrier (Heijman et al., 2012). For many years, 
the most widely accepted hypothesis to explain functional re-entry was the leading 
circle model of Allessie et al. (1973). More recently, the spiral wave hypothesis has 
become much more widely accepted. According to the leading circle model, re-entry 
circuits establish themselves in the smallest possible pathway that can sustain re-
entry (i.e. In a pathlength equal to the wavelength). Shortened refractory period and 
reduced conduction velocity reduce wavelength, allowing a greater number of 
simultaneous re-entry circuits to be accommodated thus promoting leading circle re-
entry. In contrast, according to the spiral wave model, re-entry circuits adopt the 
shape of a rotor that propagates around an excitable but unexcited core (Jalife et al., 
2009). 
Re-entry, substrate vulnerability and AF are favoured by short refractory 
periods, slow impulse conduction, structural heterogeneities and enhanced spatial 
dispersion of refractoriness (Jones et al., 2012). Refractory period is governed by 
APD, which is determined by the balance of inward and outward currents during the 
action potential plateau (Nattel et al., 2002a). Ion channel dysfunction characterized 
by increased plateau outward K+ currents and/or reduced inward ICaL accelerates 
repolarization, shortening APD and refractoriness, thereby facilitating re-entry 
(Schotten et al., 2011; Wakili et al., 2011). For example, AF-induced remodeling 
reduces ICaL and causes pronounced shortening of APD and refractory period (Yue 
et al., 1997).  
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Cardiac conduction velocity is determined by (1) electrical coupling through 
gap junction channels and (2) the maximum upstroke velocity of the phase 0 inward 
Na+ current (INa+). Gap junctions, comprised of transmembrane proteins called 
connexins, are the subcellular structures that permit electrical continuity between 
adjescent cells, and are critical for atrial impulse propagation. The heart expresses 
four primary connexin isoforms but in the atrial myocardium, the dominant isoforms 
are Connexin 43 (Cx 43) and Connexin 40 (Cx 40) are the dominant isoforms. 
Impaired gap junction coupling and connexin dysfunction, as occurs in animal 
models of AF-induced remodeling (Van der velden et al., 2000) and in human AF 
associated with fibrosis (Luo et al., 2007), reduce conduction velocity and promote 
re-entry. Cx 43 appears to play a particularly important role in AF. Lowered atrial Cx 
43 is found in chronic AF patients (Kostin et al., 2002) and animal models of AF 
(Igarashi et al., 2012) and predisposes the atrium to AF (Thibodeau et al., 2010; 
Tuomi et al., 2011). Because altered connexin proteins are both observed widely in 
AF and also serve as important substrates promoting arrhythmia maintenance (in 
the case of Cx 43), connexins were a useful marker for AF substrate and inducibilty 
in this thesis.  
Re-entry is also favoured by enhanced spatial heterogeneity of refractoriness, 
such as during vagally-mediated AF (Wang et al., 1996; Liu and Nattel., 1997). 
Dispersion of refractoriness introduces functional obstacles that promote fibrillatory 
conduction and stabilize the leading sources of re-entry circuits (rotors).  
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1.2.3 Role of the autonomic nervous system in the pathogenesis of AF 
1.2.3.1 Atrial autonomic innervation 
The autonomic nervous system of the heart includes both extrinsic and 
intrinsic components (Armour, 2004), both of which have been implicated in atrial 
arrhythmogenesis. Extrinsic sympathetic influences on the heart include both 
circulating catecholamines from the adrenal medulla and sympathetic efferent 
innervation originating from cervical, stellate and thoracic ganglia (Kawashima, 
2005). The efferent parasympathetic nerve supply consists of vagal nerves that 
originate from medullary nuclei such as the nucleus ambiguus (Linz et al., 2013). 
In addition to the extrinsic cardiac ANS, the heart is also innervated by an 
extensive intrinsic cardiac autonomic nervous system (ICANS). The ICANS forms a 
complex neural network consisting of ganglionated plexi (GP) housed within a 
number of interconnected epicardial fat pads (Armour et al., 1997). The GP contain 
both parasympathetic and sympathetic elements (Ardell, 1994) but acetyltransferase 
immunostaining of all neurons in guinea pig posterior GP indicates major cholinergic 
input to the myocardium (Mawe et al., 1996; Tuomi et al., 2010). The GP receive 
both sympathetic and parasympathetic extrinsic innervation and may modulate the 
interactions between the extrinsic and intrinsic cardiac autonomic nervous systems, 
acting as a “mini brain” on the heart (Hou et al., 2007). 
 
1.2.3.2 Autonomic regulation of atrial electrophysiology and AF 
During parasympathetic stimulation, acetylcholine released from cholinergic 
nerve terminals binds to and activates muscarinic receptors expressed by the atrial 
myocardium. Five muscarinic receptor subtypes, M1-M5, have been cloned. M1, M3 
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and M5 receptors are Gαq-coupled, while M2 and M4 receptors are coupled to 
Gαi/o (Jones et al., 2012). In the atria, M2 receptors are the most abundantly 
expressed (Krejci & Tucek, 2002) and, traditionally, have been considered the sole 
cardiac muscarinic receptor subtype. More recently, it has been established that 
atrial M3 receptors have numerous physiological functions (Shi et al., 1999b; Wang 
et al., 2007; Wang et al., 2004). The M2 and M3 subtypes activate distinct potassium 
currents: the acetylcholine-activated inward rectifying K+ current (IKACh) by M2 
receptors (Reuveny et al., 1994) and the M3 receptor-mediated potassium current 
(IKM3) by M3 receptors (Shi et al., 1999a, 1999c; Shi et al., 2004). M3 receptors may 
also contribute to the activation and desensitization of IKACh (Wang et al., 2007). 
Activation of IKACh facilitates an outward hyperpolarizing K+ current that shortens 
APD and AERP, thereby facilitating re-entry and AF (Kovoor et al., 2001). M3 
receptor-mediated activation of IKM3 results in membrane hyperpolarization and APD 
shortening (Shi et al., 2003; Shi et al., 1999a; Wang et al., 1999), which may 
facilitate re-entry in a manner similar to IKACh. Studies of transgenic mice have 
shown that both enhanced M2 (Posokhova et al., 2013) and M3 (Tuomi et al., 2010) 
receptor function in the atria are associated with enhanced susceptibility to 
electrically induced AF. 
Owing to the heterogeneous distribution of vagal innervation, muscarinic 
receptors and/or IKACh (Lomax et al., 2003) in the atria, the effect of cholinergic 
stimulation on refractory period is spatially heterogeneous (Liu and Nattel, 1997). 
The spatially heterogeneous effect of acetylcholine on refractoriness has been 
shown to promote fibrillatory conduction and spiral wave re-entry in a detailed 
mathematical model of vagal AF (Kneller et al., 2002; Schotten et al., 2011). 
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Similarly, findings from optical mapping studies of sheep atria suggest that vagally-
induced AF is maintained by a high-frequency mother rotor in the left atrium with 
fibrillatory conduction towards the right (Mandapati et al., 2000; Skanes et al., 1998; 
Mansour et al., 2001; Jalife et al., 1998; Jalife et al., 2009). Acetylcholine 
administration has also been shown to produce AF composed of multiple wavelets 
wandering through the atria in a chaotic pattern without a single source dominating 
the activation pattern (Schotten et al., 2011; Allessie et al., 1985).  
Adrenergic regulation of atrial electrophysiology occurs primarily via β1- (β1-
AR) and β2-adrenergic receptors (β2-AR), with β1-AR comprising 70-80% of all 
adrenergic receptors in the atria (Arora, 2012). Catecholamine binding to β-
adrenergic receptors causes activation of adenyl cyclase, leading to cAMP 
production and subsequent protein kinase A (PKA)-mediated phosphorylation of 
several Ca2+ handling proteins and ion channels, including L-type Ca2+ channels, 
phospholamban (PLN) and ryanodine type 2 receptors (RYR2) (Bers, 2002). 
Adrenergic stimulation also increases Ca2+ binding to calmodulin, leading to 
activation of Ca2+/calmodulin-dependent protein kinase type II (CaMKII), which 
phosphorylates many of the same substrates as PKA, thereby amplifying the 
adrenergic response (Chen et al., 2014). Phosphorylation of L-type Ca2+ channels 
by PKA increases Ca2+ influx via ICa,L while Phosphorylation of PLN augments 
sarcoplasmic reticulum (SR) Ca2+ loading via dissinhibition of the SR Ca2+-ATPase 
(SERCA2a) by PLN, responsible for reuptake of Ca2+ into the SR. As a result of 
RYR2 phosphorylation and greater SR Ca2+, the β-adrenergic response increases 
RYR2 channel opening probability (Bers, 2002). Together these actions increase the 
systolic Ca2+ transient and promote abnormal spontaneous sarcoplasmic reticulum 
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(SR) Ca2+ release events (Ca2+ sparks; Marx et al., 2000; Ogrodnik and Niggli, 
2010). Ca2+ sparks have been shown to promote DADs (Johnson et al., 1986; Wit 
and Boyden, 2007), suggesting a role for β-adrenergic activity in DAD-related 
triggered activity, although evidence for DAD-related triggered activity in AF is 
lacking. However, combined sympathovagal coactivation (during which APD is 
shortened by IKACh and the Ca2+ transient is enhanced) has been shown to cause 
late phase 3 EADs, triggered activity and AF initiation (Patterson et al., 2006; 
Burashnikov and Antzelevitch, 2003). 
 
1.2.3.3 Autonomic activity and AF: review of the evidence  
The importance of the autonomic nervous system (ANS) in the initiation and 
maintenance of AF has been demonstrated in many settings. In studying patients 
with paroxysmal AF, Coumel et al. (1996) noted two patterns: vagally mediated AF 
was common in young patients with structurally normal hearts while sympathetically 
mediated AF typically occurred in the presence of heart disease, and often during 
exercise or states of emotional stress. More recently, adrenergic triggers (associated 
with exercise or emotion), vagal triggers (mostly at night) and combined adrenergic 
and vagal triggers commonly preceded AF episodes in a large study of over 1,500 
patients (De Vos et al., 2008). Studies involving direct nerve recordings have 
demonstrated that simultaneous sympathovagal activation (Tan et al., 2008; Ogawa 
et al., 2007) and intrinsic cardiac nerve activity (Choi et al., 2010) are common 
triggers of AF paroxysms in animal models. A high incidence of sympathovagal co-
activation at baseline is associated with a high vulnerability to pacing-induced 
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sustained AF, suggesting that the ANS has a role in the development of persistent 
AF (Shen et al., 2011).  
The pulmonary veins and pulmonary vein-left atrial (PV-LA) junction are 
heavily innervated by GP (Tan et al., 2006; Chou et al., 2005) and several studies 
have highlighted a role for these intrinsic nerves in promoting AF. Enhanced activity 
from the PV-LA junction GP has been implicated in triggering that arises from the 
pulmonary veins (Patterson et al., 2005; Patterson et al., 2006) and their ablation 
suppresses or eliminates focal AF from PVs (Lu et al., 2009). Stimulation of the PV-
LA junction GP provides the substrate to convert PV firing to AF (Scherlag et al., 
2005) which may involve EAD-related triggered activity induced by adrenergic 
stimulation combined with vagally mediated APD and refractory period shortening 
(Patterson et al., 2005).  
 
1.3 Obstructive sleep apnea (OSA) 
1.3.1 Definition of OSA 
Obstructive sleep apnea (OSA) is a disorder in which episodes of pharyngeal 
collapse cause temporary cessations in breathing during sleep. These episodes can 
be complete (apneas) or partial (hypopneas), although both are sufficient to cause 
intermittent hypoxia (IH) and significant hypoxemia, as well as carbon dioxide 
retention. Apneas/hypopneas and their accompanying IH lead to arousals with sleep 
fragmentation, episodic intrathoracic pressure reductions from inspiration against an 
occluded airway and surges of autonomic activity with each episode. Excessive 
daytime sleepiness is the main symptom of OSA, but some patients also present 
with frequent snoring, choking or gasping during sleep, recurrent arousals from 
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sleep and/or impaired concentration (Parati et al., 2012). However, evidence 
suggests that a large proportion of OSA patients are asymptomatic (Duran et al., 
2001).  
OSA is identified based on symptoms and clinical findings, but a definitive 
diagnosis requires attended overnight polysomnography in a sleep laboratory. 
During polysomnography, sleep stages, heart rate and rhythm, limb movements, 
arterial oxygen saturation, and respiratory movements and/or respiratory effort are 
recorded. These parameters enable determination of the number of obstructive 
respiratory events (lasting >10s) per hour, which is used to determine the apnea-
hypopnea index (AHI). OSA is defined as an AHI of at least 5 (Parati et al., 2012), 
and the severity of OSA is defined as: mild OSA, AHI of 5-15/h; moderate OSA, AHI 
of 15-30/h, or severe OSA, AHI >30/h; Parati et al., 2012. Reduction in blood-oxygen 
saturation by at least 90% has also been described as an important indicator of OSA 
severity as it is correlated with susceptibility to cardiovascular events (Nieto et al., 
2000). 
 
1.3.2 Clinical relevance of OSA 
Data from large scale population studies in Wisconsin (Young et al., 1993), 
Pennsylvania (Duran et al., 2001) and Spain (Bixler et al., 1998) conducted using 
polysomnography suggest that OSA of at least mild severity (AHI > 5) affects 17-
26% of men and 9-28% of women. However, these studies likely underestimated the 
true disease burden of OSA, as over 85% of patients with OSA remain undiagnosed 
(Young et al., 1997; Kapur et al., 2002). The prevalence of OSA increases with age 
in both men and women (Duran et al., 2001; Young et al., 2004). Obesity is also a 
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major OSA risk factor, as a 10% increase in weight corresponds with a 6-fold 
increased risk of developing OSA of at least moderate severity and a 32% increase 
in the AHI (Peppard et al., 2000a).  
OSA has been linked to the development of a multitude of complications 
including cardiovascular, metabolic and neurocognitive consequences. In particular, 
the cardiovascular consequences of OSA contribute significantly to population 
morbidity and mortality. OSA has been recognized as an independent risk factor for 
hypertension (Peppard et al., 2000b; Nieto et al., 2002), stroke (Arzt et al., 2005), 
and coronary artery disease (Sorajja et al., 2008; Mooe et al., 2001). OSA is 
associated with increases in rates of cardiovascular morbidity and mortality 
independent of other risk factors (Marin et al., 2005; Yaggi et al., 2005; Campos-
Rodriguez et al., 2012) and treatment of OSA with continuous positive airway 
pressure (CPAP) has been demonstrated to reduce cardiovascular risk (Marin et al., 
2005; Campos-Rodriguez et al., 2012). 
OSA is also an independent risk factor for AF (Mehra et al., 2006). The 
prevalence of OSA was 20% greater among AF patients compared to healthy 
individuals matched for age, sex, BMI, prevalent hypertension and heart failure 
(Gami et al., 2004). Similarly, the prevalence of AF was 5 times greater in adults with 
OSA than in those without the syndrome (4.8% vs 0.9%; Mehra et al., 2006). OSA is 
also associated with increased AF reoccurrence rates after cardioversion and 
ablation (Ng et al., 2011). The finding that treatment of OSA with continous positive 
airway pressure reduces the risk of recurrence of AF suggests a causal role for OSA 
in the pathogenesis of AF (Kanagala et al., 2003; Fein et al., 2013; Naruse et al., 
2013), but the underlying mechanisms are unknown. 
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1.3.3 Intermittent hypoxia in OSA 
 OSA is a multicomponent disorder involving IH, sleep fragmentation, 
intrathoracic pressure swings and obstructed respiratory efforts. Together, these 
components contribute to the disease progression and development of OSA-related 
comorbidities (For review, see Dempsey et al., 2010). However, the widespread use 
of IH in animals to model OSA has enabled the recognition that IH is likely the most 
critical component underlying its cardiovascular complications (Dematteis et al., 
2009).  
 
1.3.3.1 IH model 
 Since their introduction over 20 years ago (Fletcher et al., 1992a, 1992b, 
1992c), animal models employing IH have been used widely to investigate the 
pathophysiology of OSA and its consequences. Animals, typically rodents, are 
exposed to intermittent cycles of hypoxia-reoxygenation during their sleep cycles to 
emulate the oxygen desaturations caused by obstructive apneas. The IH stimulus is 
typically applied during the day, throughout the sleep cycle of nocturnal animals 
such as rodents, but with significant differences with respect to the duration of 
daytime exposure, number of cycles per hour and level of fraction of inspired O2 
(FiO2). The IH stimulus may be applied up to 60 (Campen et al., 2005; Polotsky et 
al., 2006) or 120 (Fletcher et al., 1992c) times per hour, with FiO2 levels typically in 
the range of 5-10% (Fletcher et al., 1992c; Soukhova-O’Hare et al., 2006). These 
oxygen desaturations are well correlated with those observed in OSA patients (Jun 
et al., 2010; Louis and Punjabi, 2009), and reliably produce the same physiological 
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perturbations that occur in the human disease, including profound effects on 
autonomic activity, heart rate and blood pressure.  
 
1.3.3.2 Effects of IH on the autonomic nervous system and the heart  
Hypoxia is sensed by specialized structures located in the carotid bodies 
known as peripheral chemoreceptors, which become activated during apneic 
episodes. The activation of these structures sets in motion a cascade of acute 
autonomic adjustments to maintain homeostasis during hypoxia, collectively referred 
to as the peripheral chemoreflex (For review, see Prabhakar, 2000). Paradoxically, 
chemoreceptor activation results in simultaneous activation of both vagal and 
sympathetic outflows to the heart in both dogs (Kollai and Koizumi, 1979) and rats 
(Boscan et al., 2001). The net response of the heart to chemoreceptor stimulation is 
profound bradycardia (Braga et al., 2008), indicating that the vagal effect overrides 
positive chronotropism of the sympathetic activation, and a positive inotropic 
response that is sympathetically mediated (Braga et al., 2007). In addition to these 
primary effects on cardiac autonomic activity, chemoreflex activation also causes 
sympathetically mediated vasoconstriction, resulting in acute surges in blood 
pressure (Haibara et al., 1995; Braga et al., 2008). These surges are detected by 
mechanosensitive arterial baroreceptors in the aortic arch, triggering activation of the 
associated arterial baroreflex which elicits sympathoinhibitory effects on the 
vasculature while further increasing parasympathetic activation of the heart (Braga 
et al., 2008). Thus, during IH and episodes of apnea the atria are bombarded by 
both sympathetic and parasympathetic activity. 
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Chronic repetition of these acute nocturnal hypoxic episodes leads to 
substantial autonomic dysfunction. As occurs in patients with OSA (Narkiewicz et al., 
1999), peripheral chemoreflex sensitivity and the hemodynamic responses to 
peripheral chemoreceptor activation are potentiated in rodents exposed to chronic 
repetitive IH (Braga et al., 2006; Huang et al., 2009). At the same time, arterial 
baroreflex sensitivity and/or baroreflex control of sympathetic activity is reduced in 
OSA patients (Carlson et al., 1996; Narkiewicz et al., 1998) and following exposure 
to IH in animal models (Lin et al., 2007). As a result, subjects with repetitive sleep 
apneic events exhibit persistently elevated sympathetic tone and hypertension even 
during awake hours when there is an absence of apneas (Narkiewcz et al., 1999; 
Sajkov et al., 1994). Accordingly, chronic IH exposure leads to hypertension 
(Fletcher et al., 1992a; Fletcher et al., 1992c), elevated plasma catecholamines 
(Zoccal et al., 2007; Gonzalez-Martin et al., 2009; Peng et al., 2014), and elevated 
cervical (Greenberg et al., 1999), renal (Huang et al., 2009), splanchnic (Dick et al., 
2007; Xing and Pilowsky, 2010), thoracic (Zoccal et al., 2008) and lumbar (Marcus et 
al., 2010) sympathetic nerve activity in rodent IH models of sleep apnea. The chronic 
effects of IH on parasympathetic nervous activity (PNA) are less well understood, 
but enhanced vagal efferent control of heart rate following chronic IH in rats (Gu et 
al., 2007) and mice (Lin et al., 2007) suggests that activity of peripheral vagal 
neurons become upregulated, to compensate for the loss of baroreflex control of the 
heart.  
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1.3.3.3 Implications for atrial arrhythmias 
IH exerts a myriad of effects on the autonomic nervous system with potential 
implications for atrial arrhythmogenesis. During sleep, bouts of hypoxia cause 
repetitive oscillations in parasympathetic and sympathetic cardiac outflow that may 
predispose the atria to autonomically triggered arrhythmias. As previously 
mentioned, simultaneous sympathovagal activation (Tan et al., 2008; Ogawa et al., 
2007; de Vos et al., 2008) and activity of intrinsic cardiac nerves (Choi et al., 2010) 
are common triggers of AF episodes. Moreover, AF can be initiated by stimulation of 
GPs (Scherlag et al., 2005), β-adrenergic agonists (Sharifov et al., 2004) and 
cholinergic agonists (Sharifov et al., 2004; Mandapati et al., 2000; Skanes et al., 
1998; Mansour et al., 2001; Jalife et al., 1998; Allessie et al., 1985). In addition to 
having substantial acute effects on autonomic activity, repeated and chronic 
exposure to IH results in sustained autonomic dysfunction during wakefulness, 
which may give rise to atrial electrophysiological alterations and provide the 
necessary triggers and vulnerable substrate for AF. Abnormal autonomic function 
and/or changes in autonomic tone are associated with electrophysiological substrate 
development and AF in animal models (Jayachandran et al., 2000; Chang et al., 
2001; Guasch et al., 2013) and human patients (Nguyen et al., 2009). The setting of 
autonomic dysfunction caused by IH may operate similarly to augment substrate 
vulnerability and AF susceptibility. 
 
1.4 RATIONALE 
Although substantial evidence from epidemiological and clinical studies 
suggests a causal role for OSA in the pathogenesis of AF, the use of animal IH 
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models to characterize this relationship is lacking and the underlying mechanisms 
have not been adequately investigated. IH has been implicated in mediating many 
consequences of OSA including substantial autonomic dysfunction and enhanced 
sympathetic drive, but the role of IH in predisposing to AF is not known. Given that 
IH bombards the atria with autonomic activity and augments chronic autonomic 
dysfunction, both of which have been implicated in AF promotion, IH may augment 
substrate formation and predispose the atria to AF.  
 
1.5 HYPOTHESIS AND OBJECTIVES 
We hypothesized that IH augments formation of electrophysiological and 
autonomic substrates for AF and increases susceptibility to electrically induced AF. 
 
Specific objectives of this thesis were to determine in the rat: 
1. the effect of IH on the expression of adrenergic and muscarinic receptor 
mRNA and protein in the atria; 
2. the effect of IH on atrial connexin mRNA and protein expression; 
3. the effect of IH on atrial effective refractory period (AERP) and the 
susceptibility to electrically-induced AF;, and 
4. the role of the autonomic nervous system in mediating atrial 
electrophysiological alterations and enhanced AF susceptibility induced by 
IH. 
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2.0 MATERIALS AND METHODS 
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2.1 Animals 
All procedures were in accordance with the Guidelines on the Care and Use 
of Laboratory Animals of the Canadian Council on Animal Care and the Animal Use 
Committee at the University of Western Ontario (Protocol #’s 2006-122, 2008-030 & 
2014-053). A total of 149 adult, male Sprague-Dawley rats (Charles River, Canada) 
weighing 275 – 400 g were included in this study. Rats were housed at a 
temperature of 22 ± 1 °C with 60% relative humidity, under 12/12 hour light/dark 
cycle. Food and water were provided ad libitum, except during exposure to IH or 
normoxic conditions. 
 
2.2 Intermittent hypoxia model of Obstructive Sleep Apnea 
OSA was modeled by exposing rats to repetitive cycles of hypoxia-
reoxygenation during their sleep cycles (9 am to 5 pm) to mimic that caused by 
obstructive apneas, as described previously (Moreau and Ciriello, 2013). For 8 hours 
per day (9 am to 5 pm), rats were placed in plexiglass® chambers containing 4 
tubes in which they were allowed to move freely. In the IH chamber, computerized 
solenoid valves which regulated the inflow of pressurized air and nitrogen were 
programmed to produce cycles of 80 seconds of hypoxia (6.5-7% O2) followed by 
120 seconds of reoxygenation (21% O2 ; Figure 1.1A).  This particular regimen 
emulates a moderate form of OSA, based on the apnea-hypopnea index (AHI; 
Moreau and Ciriello, 2013; Parati et al., 2012). Fans pushed the gasses through a 
mixing chamber prior to entering the chamber containing the animal tubes (Figure 
1.1B). Sensors on the chamber continuously monitored oxygen and carbon dioxide 
levels, which allowed the computer to ensure proper cycling and maintaince of 
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eucapnic conditions (<0.1% CO2). Normoxic control animals were placed in identical 
chambers through which only pressurized room air cycled through the system. To 
observe acute, intermediate and chronic effects of the model, animals were exposed 
to IH or normoxic conditions for an overall exposure duration of 1, 7 or 95 days, 
respectively (Messenger et al., 2013; Moreau and Ciriello, 2013). There were no 
obvious differences in sleep patterns between the IH and normoxia-exposed rats in 
the chambers.  
 
2.3 Animal subgroups 
For real-time PCR analysis, atrial mRNA from IH and normoxia-exposed rats 
were compared immediately after 1 day (n = 7 per group), 16 hours after 1 day (n = 
5 normoxic rats, n = 6 IH rats), 16 hours after 7 days (n = 8 per group) and 
immediately after 95 days of exposure (n = 8 per group). For western blot analysis, 
atrial protein levels from IH and normoxia exposed rats were compared immediately 
following 1 day (n = 7 per group), 16 hours after 1 day (n = 5 normoxic rats, 6 IH 
rats), immediately after 7 days (n = 7 per group) and 16 hours after 7 days of 
exposure (n = 7 per group). Rats exposed to IH (n = 27) or normoxia (n = 27) for 7 
days underwent intracardiac electrophysiological studies immediately after 
exposure.  
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Figure 2.1 Intermittent hypoxia exposure model and chamber 
(A) O2 nadir (%) in the hypoxia chamber during a single cycle. (B) Schematic 
representation of the chamber used for IH exposures. Thick black lines represent 
tubing and thin black lines represent electrical connections. Arrows indicate direction 
of air flow. Animals are housed within the hypoxia chamber (1), which was attached 
to a zero-pressure escape valve (2) that prevented pressure changes within the 
chamber. Fans (3) promoted air flow from the animal chamber to the mixing 
chamber (4) which included baffles to encourage mixing of fresh gases with gases 
flowing through the system. The inflow of 100% compressed nitrogen (5) and 
pressurized room air (6) into the mixing chamber was controlled by solenoid valves 
(7) controlled by a computerized timing box (8) that received feedback from O2 (9) 
and CO2 (10) sensors. Taken with permission from Moreau, 2013.  
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2.4 Tissue collection  
Rats subjected to IH or normoxic conditions for 1, 7 or 95 days were 
sacrificed and the hearts exposed using a thoracotomy approach. Right and left atria 
were excised and collected in Eppendorf tubes, rapidly immersed in liquid nitrogen 
and then stored at -80 °C until mRNA or protein analysis. Samples of total atria were 
partitioned into two halves to be further processed for isolation of RNA and protein. 
 
2.5 RNA isolation and real-time PCR 
Total atrial RNA was isolated using TRIZOL reagent (Life Technologies, 
Railey, UK) and RNA concentrations were determined with a NanoDrop2000 UV-vis 
spectrophotometer (ThermoFisher Scientific, Toronto, ON). RNA integrity was 
evaluated by visual assessment of ethidium bromide-stained agarose denaturing 
gels. cDNA was synthesized from extracted RNA using qScript cDNA SuperMix 
(Quanta BioSciences, Gaithersburg, MD). Oligonucleotide primer sequences for the 
M2 receptor, M3 receptor, Cx 40, Cx 43, β1-AR, β2-AR and ribosomal subunit 18S 
are shown in Table 1. Real-time PCR was carried out in triplicate parallel reactions 
on a Bio-Rad CFX384 (Bio-Rad, Hercules, CA) using the SsoFast EvaGreen 
Supermix system (Bio-Rad). Amplification was performed at 95ºC for 3 min, followed 
by 39 cycles at 95ºC for 15 s, 59ºC for 15 s and 72ºC for 15 s. Signal detection and 
analysis were performed using Bio-Rad CFX384 software (Bio-Rad). Amplification 
specificity was assessed based on the presence of a single, narrow melting curve 
peak for each assay. Fold differences, normalized to ribosomal subunit 18S were 
determined using the comparative ∆∆ CT method. 
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Table 2.1 Primer sequences used for real time PCR 
Gene   Primer sequence 
  
 
  
M2 receptor Forward 5'-GCCCCAGCCATTCTCTTCTG-3' Reverse 5’-TATTCTGCTCTTGCTCGCCCG-3’ 
   M3 receptor Forward 5’-TGCCTGGGTCTCTTAATTCC-3’  
Reverse 5’-CTTCACATGGGATCTGGATG-3’ 
   Cx 43 Forward 5’-TCCTTGGTGTCTCTCGCTTT-3’ Reverse 5’-GAGCAGCCATTGAAGTAGGC-3’ 
! ! !Cx 40 Forward 5’-ATGGGTGACTGGAGCTTCCTGGGG-3’ 
Reverse 5’-TCACACTGACAGGTCATCTGACCT-3’ 
! ! !
β1-AR Forward 5′-ACCCCAAGTGCTGCGATTTCGT-3′ Reverse 5′-GCTCGCAGCTGTCGATCTTCTT-3′ 
! ! !
β2-AR Forward 5′-TTCTGTGCCTTCGCCGGTCTTCTT-3′ Reverse 5′-ATGCCAGGGGCTTCCTCACAAA-3′ 
! ! !18S Forward 5’-GTGACGGGGAATCAGGGTT-3’ Reverse 5’-CCTTCCTTGGATGTGGTAGCC-3’ 
!! !! !!
 
 
 
 
 
 
 
2.6 Protein isolation and western blot 
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Protein lysates were prepared in RIPA buffer (50 mM Tris, 150 mM sodium 
chloride, 0.1% SDS, 1% Triton-X 100, 0.5% sodium deoxycholate, 1mM EDTA, 1mM 
sodium orthovanadate, 1 mM sodium fluoride, 25 mM β-glycerophosphate, pH 7.5) 
with a protease inhibitor cocktail Tablet (Roche Applied Science; Laval, PQ). Tissue 
homogenization was performed on ice, with delivery of 3, 15-second bursts from a 
Kinematica polytron homogenizer set to 60% (Brinkmann Instruments; Rexdale, 
ON). Homogenates were then sonicated over 3 passages for 15 seconds each on 
ice (55%; Sonic Dimembrator Model 150; Fisher Scientific) and then centrifuged at 
4°C for 30 min at 14 500 x g. Protein concentrations were determined using the Bio-
Rad DC protein assay kit (Bio-Rad; Hercules, CA).  
Samples containing 20-30 µg protein were heated at 75ºC for 5 minutes prior 
to being loaded onto 10% polyacrylamide gels and subjected to electrophoretic 
separation by size in the Mini-Protean II cell from Bio-Rad. Dose-response curves of 
various protein amounts (0.1-33 µg) were generated to ensure that the chosen 
amount of total protein was in the linear range of detection. Resolved proteins were 
transferred onto polyvinylidene fluoride (0.45 µm) membranes (Millipore; Billerica, 
MA) in a Mini Trans-Blot Transfer Cell (Bio-Rad). Buffer containing 5% skim milk, 
Tris-buffered saline with 0.01% Tween-20 (TBS-T; 20 mM Tris, 0.5 M NaCl, 0.1% 
Tween-20; pH 8.0) was used to reduce nonspecific binding and for the dilution of 
primary and secondary antibodies. Using routine procedures, (Moreau and Ciriello, 
2013) membranes were probed overnight with primary antibodies at 4ºC, including 
rabbit anti-connexin 43 (1:10,000; C6219, Sigma-Aldrich, St. Louis, Missouri), rabbit 
anti-connexin 40 (1:8000; AB101929, Abcam Inc., Cambridge, MA), rabbit anti-β1-
adrenergic receptor (1:2000; PA1-049, ThermoFisher Scientific; Rockford, IL), rabbit 
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anti-M2 muscarinic acetylcholine receptor (1:800; AB5166; Millipore; Billerica, MA), 
and polyclonal rabbit anti-M3R (1:1000; sc-9108, Santa Cruz Biotechnology; Santa 
Cruz, CA). After washing, membranes were probed again for 1 hour at room 
temperature with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:10,000; 
CLCC27007, Cedarlane Laboratories, Burlington, ON) as the secondary antibody. 
Bands were detected using SuperSignal West Pico Chemiluminescent Substrate 
(ThermoFisher Scientific; Toronto, ON), visualized using a VersaDoc imaging 
system (Bio-Rad Labortories; Hercules, CA) and analyzed using QuantityOne 
version 4.6.6 software (Bio-Rad Laboratories; Hercules, CA). Membranes were 
exposed for 10-40 seconds. This software highlights saturated pixels, which enabled 
us to ensure that exposure never reached saturation.  
To control for differences in protein loading, following detection of the initial 
protein, membranes were incubated with stripping buffer (200 mM Glycine, 6.9 mM 
SDS, 0.01% Tween-20, pH 2.2) and immunoblotting was performed again, using 
mouse anti-β-tubulin (1:2000, T8328; Sigma-Aldrich, St. Louis, Missouri) as the 
primary antibody followed by horseradish peroxidase-conjugated goat anti-mouse 
IgG (1:8000, 170-6516, Bio-Rad Laboratories; Hercules, CA) as the secondary 
antibody with chemiluminescence detection as described above.  
 
2.7 Preoperative procedures 
A subset of rats underwent in vivo intracardiac electrophysiological studies 
following exposure to IH (n = 27) or normoxia (n = 27) for 7 days.  At the end of the 
exposure period, rats were anesthetized with an intraperitoneal injection of a mixture 
of ketamine (100 mg/kg) and xylazine (10 mg/kg) and fixed in a supine position over 
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a heated water blanket. A small animal rectal probe (YSI-402; Yellow Springs 
Instruments, Yellow Springs, OH) was used for continuous monitoring of body 
temperature, which was maintained within the normal physiological range (36.5–
38°C) by adding or removing heat from lamps and heated water-filled gloves.  
 
2.8 Electrocardiogram (ECG) Recordings 
Standard ECG limb leads I, II, III, aVR, aVL and aVF were recorded 
continuously throughout the study using four 25-gauge subcutaneous platinum 
electrodes (Grass Instrument, Quincy, MA) placed at the base of each limb. ECG 
signals were sampled at 1.5 kHz and filtered (0.05 – 100 Hz) with an ECG 100 
preamplifier connected to an MP100 recording system (BIOPAC Systems, Biolynx, 
Montreal, PQ, Canada).  
 
2.9 Intracardiac electrophysiological studies 
A 2-Fr octapolar stimulation/recording/drug infusion catheter (CIB’ER Mouse, 
NuMED, Hopkinton, NY) was inserted through the right jugular vein and advanced 
into the right atrium. The catheter was placed at the site where the amplitude of the 
atrial deflection exceeded that of the ventricular deflection in the intracardiac 
electrograms recorded from the two proximal pairs of bipolar electrodes. Bipolar 
pacing used 2-ms pulses at twice the diastolic threshold, delivered through a Grass 
SIU5 stimulus isolation unit, connected to a Grass S88 stimulator, programmed with 
a custom-built timer, as previously described (Tuomi et al., 2010). Atrial effective 
refractory period (AERP) measurements were made using cycle lengths of 150 ms 
and 100 ms in a conditioning train of 8 basic drive stimuli (S1 x 8) followed by a 
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premature extrastimulus (S2). The S2 was delivered at decrements of 10 ms, 
followed by 1 ms decrements as AERP was approached. AERP was defined as the 
longest S1-S2 coupling interval that failed to elicit an atrial response.  
Both programmed electrical stimulation (PES) and burst pacing (2 ms pulses 
at 50 Hz applied for 1 second, up to 10 times per atrial site) were used to determine 
susceptibility to atrial arrhythmia induction. AF was identified based on the presence 
of intra-atrial electrogram fractionation and characteristics of the surface lead 
electrograms: lack of regular P waves and “irregularly, irregular” ventricular 
responses. 
 
2.10 In vivo electrophysiological study design  
After performing electrophysiological studies at baseline as described above, 
pacing protocols were repeated following administration of muscarinic and 
adrenergic receptor agonists and antagonists. IH or normoxia-exposed rats were 
assigned to 1 of 3 groups, each receiving a different drug regimen. In IH (n = 10) or 
normoxia (n = 9) exposed rats assigned to group 1, electrophysiological 
measurements were made sequentially at baseline, then in the presence of 
isoproterenol, then again at baseline after a 40 minute washout period, followed by 
in the presence of propranolol, then isoproterenol. In group 2 (n = 8 per condition), 
measurements were made at baseline, followed by in the presence of carbachol, 
then at baseline after a 60 minute washout period, followed by in the presence of 
atropine, then carbachol. In IH (n = 6) or normoxia (n = 5) exposed rats assigned to 
group 3, the measurements were made at baseline, followed by in the presence of  
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Figure 2.2 Electrophysiology protocol and experimental design 
Flow chart showing the electrophysiological protocol (EP; panel A) and experimental 
design (panel B). AERP, atrial effective refractory period; AF, atrial fibrillation; PES, 
programmed electrical stimulation. 
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carbachol, again at baseline after 60 minutes for washout, followed by in the 
presence of darifenacin, then carbachol. The electrophysiological protocol and 
experimental design are shown in Figure 2.1. 
 
2.11 Adrenergic and muscarinic receptor drugs 
All drug doses and routes of administration were selected based on previous 
literature and the results of pilot studies undertaken to observe heart rate responses 
to cumulative doses within ranges expected to produce moderate (10-30%) changes 
in heart rate (please see the appendix for details). In individual rats, responses to at 
least two doses of each drug or dose-response relationships were observed (refer to 
the appendix). The M3 receptor-selective antagonist darifenacin hydrobromide (1.0 
mg/kg; Cedarlane Laboratories, Markham, ON) was dissolved in a vehicle containing 
isotonic saline and DMSO (in a 1:1 v/v ratio) and administered intravenously. All 
other drugs, including the nonselective muscarinic agonist carbachol (0.05 mg/kg; 
Sigma, Mississauga, ON), the nonselective muscarinic antagonist atropine (1.0 
mg/kg; Sigma), the nonselective β-agonist isoproterenol (0.1 mg/kg; Sigma) and the 
nonselective β-antagonist propranolol (10 mg/kg; Sigma) were dissolved in isotonic 
saline and administered intraperitoneally.  
 
2.12 Statistical analysis 
All values are expressed as mean ± standard error of the mean. For protein 
and gene expression analyses, comparisons between IH and normoxia exposed 
animals at the different time points were made using unpaired, two-tailed Student t-
tests (GraphPad Prism 6; GraphPad Software, San Diego, CA). Discrete data were 
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analyzed by Chi squared analysis (GraphPad Prism 6; GraphPad Software, San 
Diego, CA). Drug and groupwise comparisons used two-way ANOVA using 
GraphPad Prism 6 software. In all comparisons, a p-value < 0.05 was considered 
statistically significant. 
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3.0 RESULTS 
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3.1 Expression of muscarinic receptors 
Figure 3.1 shows that atrial M2 receptor protein was significantly higher 
immediately following both 1 (P < 0.01) and 7 (P < 0.05) days of IH exposure 
compared to normoxic controls. However, no significant differences were present 
between the IH and normoxia-exposed rats approximately 16 hours after the end of 
the exposure periods, suggesting that this effect is reversible at the 1 and 7 day time 
points. As shown in Figure 3.2, M2 receptor mRNA levels were not significantly 
different following IH exposure for 1, 7 or 95 days, indicating that elevated M2 
receptor protein content in the IH rats was not due to increased gene expression; 
rather, reduced protein degradation and/or an increase in translation may be 
responsible for the changes we observed. Compared to normoxic controls, M3 
receptors were also higher in 1 day IH-exposed rats at the protein level (Figure 3.3; 
P < 0.01) and at the mRNA level (Figure 3.4; P < 0.05).  
 
3.2 Expression of adrenergic receptors 
Rats exposed to 1 or 7 days of IH exhibit no change in β1-adrenergic receptor 
content at the protein (Figure 3.5) or mRNA (Figure 3.6) level. However, β1-
adrenergic receptor mRNA was significantly lower in rats exposed to IH for 95 days 
compared with normoxic controls (Figure 3.5; P < 0.05). On the other hand, in the 
atria of IH-exposed rats, β2-adrenergic receptor mRNA levels were not significantly 
different from normoxic controls at any of the exposure lengths studied (Figure 3.7) 
and corresponding protein levels were not investigated.  
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Figure 3.1 Effect of intermittent hypoxia on atrial M2 receptor protein 
expression 
Bar graphs (A) and representative blots (B-E) showing M2 muscarinic receptor 
(M2R) protein expression as a ratio of β-tubulin in the atria of adult male rats 
exposed to intermittent hypoxia or normoxic conditions for 8 hours per day for 1 or 7 
days. Rats were sacrificed immediately after IH or normoxia exposure (1 dayi and 7 
daysi) or the day after exposure, following a 16 hour delay (1 dayd and 7 daysd), and 
each time point was run on separate gels. Data shown are means ± SEM. *, P < 
0.05; **, P < 0.01; N.S., not significant. 
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Figure 3.2 Effect of intermittent hypoxia on atrial M2 receptor mRNA 
expression 
Bar graphs showing no difference in M2 muscarinic receptor (M2R) mRNA 
expression as a ratio to 18S in the atria of adult male rats exposed to intermittent 
hypoxia or normoxic conditions for 8 hours per day for 1, 7 or 95 days. Rats were 
sacrificed immediately after IH or normoxia exposure (1 dayi) or the day after 
exposure, following a 16 hour delay (1 dayd, 7 daysd and 95 daysd). Data shown are 
means ± SEM. N.S., not significant. 
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Figure 3.3 Effect of intermittent hypoxia on atrial M3 receptor protein 
expression 
Bar graphs (A) and representative blots (B-E) showing M3 muscarinic receptor 
(M3R) protein expression as a ratio of β-tubulin in the atria of adult male rats 
exposed to intermittent hypoxia or normoxic conditions for 8 hours per day for 1 or 7 
days. Rats were sacrificed immediately after IH or normoxia exposure (1 dayi and 7 
daysi) or the day after exposure, following a 16 hour delay (1 dayd and 7 daysd) and 
each time point was run on separate gels. Data shown are means ± SEM. **, P < 
0.01; N.S., not significant. 
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Figure 3.4 Effect of intermittent hypoxia on atrial M3 receptor mRNA 
expression 
Bar graphs showing M3 muscarinic receptor (M3R) mRNA expression relative to 
18S in the atria of adult male rats exposed to intermittent hypoxia or normoxic 
conditions for 8 hours per day for 1, 7 or 95 days. Rats were sacrificed immediately 
after IH or normoxia exposure (1 dayi) or the day after exposure, following a 16 hour 
delay (1 dayd, 7 daysd and 95 daysd). Data shown are means ± SEM. *, P < 0.05; 
N.S., not significant. 
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Figure 3.5 Effect of intermittent hypoxia on atrial β1-adrenergic receptor 
protein expression 
Bar graphs (A) and representative blots (B-E) showing β1-adrenergic receptor (β1-
AR) protein expression as a ratio of β-tubulin in the atria of adult male rats exposed 
to intermittent hypoxia or normoxic conditions for 8 hours per day for 1 or 7 days. 
Rats were sacrificed immediately after IH or normoxia exposure (1 dayi and 7 daysi) 
or the day after exposure, following a 16 hour delay (1 dayd and 7 daysd), and each 
time point was run on separate gels. Data shown are means ± SEM. N.S., not 
significant. 
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Figure 3.6 Effect of intermittent hypoxia on atrial β1-adrenergic receptor 
mRNA expression 
Bar graphs showing β1-adrenergic receptor (β1-AR) mRNA expression as a ratio of 
18S in the atria of adult male rats exposed to intermittent hypoxia or normoxic 
conditions for 8 hours per day for 1, 7 or 95 days. Rats were sacrificed immediately 
after IH or normoxia exposure (1 dayi) or the day after exposure, following a 16 hour 
delay (1 dayd, 7 daysd and 95 daysd). Data shown are means ± SEM. *, P < 0.05; 
N.S., not significant. 
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Figure 3.7 Effect of intermittent hypoxia on atrial β2-adrenergic receptor 
mRNA expression 
Bar graphs showing β2-adrenergic receptor (β2-AR) mRNA expression as a ratio of 
18S in the atria of adult male rats exposed to intermittent hypoxia or normoxic 
conditions for 8 hours per day for 1, 7 or 95 days. Rats were sacrificed immediately 
after IH or normoxia exposure (1 dayi) or the day after exposure, following a 16 hour 
delay (1 dayd, 7 daysd and 95 daysd). Data shown are means ± SEM. N.S., not 
significant. 
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3.3 Expression of connexins 
Figure 3.8 shows that protein expression of Cx 43 was significantly lower the 
next day in the atria of rats exposed to IH for 7 days compared to normoxic controls 
(P < 0.05). This is likely at least partially due to a reduction in gene transcription, 
since lowered Cx 43 protein was accompanied by similar reductions in Cx 43 mRNA 
content, as shown in Figure 3.9 (P < 0.05). With more prolonged exposures for 95 
days, IH rats had significantly lower Cx 43 mRNA compared to normoxic controls 
(Figure 3.9; P < 0.05). IH exposure for 1 day and sacrificed immediately was 
paradoxically associated with transiently higher Cx 43 protein (Figure 3.8, P < 0.05), 
with no change in mRNA (Figure 3.9). This suggests that elevated Cx 43 protein 
content immediately following 1 day of IH was not due to increased gene expression; 
rather, reduced protein degradation and/or an increase in translation may be 
responsible. The opposing changes in Cx 43 protein at 1 versus 7 days indicates 
that the effects of IH in the atria may be biphasic, as has been demonstrated for 
numerous proteins in cardiac tissues exposed to IH (for review, see Yin et al., 2012). 
Levels of Cx 40 protein (Figure 3.10) and mRNA (Figure 3.11) were not significantly 
different in IH or normoxia exposed animals at any of the time points investigated. 
 
3.4 Electrophysiological characteristics 
After 7 days of exposure, P-wave duration, PQ interval and QT interval were 
not significantly different in IH rats compared to normoxic controls (Table 3.1). QRS 
duration could not be measured because QRS complexes were often “buried” within 
the T waves on the ECGs of rapidly beating rat hearts. However, the QT interval can 
still provide an index for ventricular conduction, since the QT represents the duration 
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of ventricular depolarization and repolarization. IH caused a trend to increase heart 
rate in IH rats (248±6 BPM versus 262±6 BPM) compared to normoxic controls was 
noted but this difference was not statistically significant (P = 0.14). 
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Figure 3.8 Effect of intermittent hypoxia on atrial connexin 43 protein 
expression 
Bar graphs (A) and representative blots (B-E) showing Connexin 43 (Cx 43) protein 
expression as a ratio of β-tubulin in the atria of adult male rats exposed to 
intermittent hypoxia or normoxic conditions for 8 hours per day for 1 or 7 days. Rats 
were sacrificed immediately after IH or normoxia exposure (1 dayi and 7 daysi) or the 
day after exposure, following a 16 hour delay (1 dayd and 7 daysd), and each time 
point was run on separate gels. Data shown are means ± SEM. *, P < 0.05, N.S., not 
significant. 
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Figure 3.9 Effect of intermittent hypoxia on atrial connexin 43 mRNA 
expression 
Bar graphs showing Connexin 43 (Cx 43) mRNA expression as a ratio of 18S in the 
atria of adult male rats exposed to intermittent hypoxia or normoxic conditions for 8 
hours per day for 1, 7 or 95 days. Rats were sacrificed immediately after IH or 
normoxia exposure (1 dayi) or the day after exposure, following a 16 hour delay (1 
dayd, 7 daysd and 95 daysd). Data shown are means ± SEM. *, P < 0.05, N.S., not 
significant. 
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Figure 3.10 Effect of intermittent hypoxia on atrial connexin 40 protein 
expression 
Bar graphs (A) and representative blots (B-E) showing Connexin 40 (Cx 40)  protein 
expression as a ratio of β-tubulin in the atria of adult male rats exposed to 
intermittent hypoxia or normoxic conditions for 8 hours per day for 1 or 7 days. Rats 
were sacrificed immediately after IH or normoxia exposure (1 dayi and 7 daysi) or the 
day after exposure, following a 16 hour delay (1 dayd and 7 daysd), and each time 
point was run on separate days. Data shown are means ± SEM. N.S., not significant. 
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Figure 3.11 Effect of intermittent hypoxia on atrial connexin 40 mRNA 
expression 
Bar graphs showing Connexin 40 (Cx 40)  expression as a ratio of 18S in the atria of 
adult male rats exposed to intermittent hypoxia or normoxic conditions for 8 hours 
per day for 1, 7 or 95 days. Rats were sacrificed immediately after IH or normoxia 
exposure (1 dayi) or the day after exposure, following a 16 hour delay (1 dayd, 7 
daysd and 95 daysd). Data shown are means ± SEM. N.S., not significant. 
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Table 3.1: Electrophysiological characteristics measured from the surface lead 
electrograms recorded from rats exposed to 7 days of IH or normoxia. 
 
Values are means ± SEM; n, number of rats. BPM, beats per minute.  
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3.5 Atrial effective refractory periods  
In both normoxia and IH-exposed rats, AERPs were spatially heterogeneous, 
with longer AERPs occurring in the high-right atrium (HRA) compared with the mid-
right atrium (MRA) at basic drive train cycle lengths of 100 ms (P < 0.01; Figure 
3.12A) and 150 ms (P < 0.05; Figure 3.12B). This finding is consistent with results of 
previous studies in which right atrial PES was performed in mice (Tuomi et al., 2010; 
Tuomi et al., 2011). Right atrial ERPs measured in IH-exposed rats at baseline were 
not significantly different from those of normoxic controls (Figure 3.12).  
 
3.6 Effects of autonomic receptor drugs on AERPs 
All measurements of AERP in IH- or normoxia-exposed rats in the presence 
and absence of carbachol, atropine, darifenacin, isoproterenol and propranolol are 
summarized in Table 3.2. Treatment with the nonselective muscarinic receptor 
agonist carbachol shortened AERP by 18-20% in normoxia-exposed rats and by 29-
31% in rats exposed to IH (Table 3.2). With carbachol administration, IH rats had a 
lower average AERP than normoxic controls at both atrial sites and drive cycle 
lengths, but these differences were not statistically significant (Figure 3.13). Two-
way ANOVA revealed a significant interaction between drug (carbachol) and 
treatment (IH versus normoxia), suggesting that rats exposed to IH may have 
enhanced cholinergic sensitivity. In contrast, the nonselective muscarinic receptor 
antagonist atropine caused similar increases in AERPs in all animals (Figure 3.14; 
Table 3.2). Following carbachol administration, AERP was measured again in the 
absence and presence of the selective M3 receptor antagonist, darifenacin, to  
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Figure 3.12 Effect of intermittent hypoxia on atrial effective refractory period 
Atrial effective refractory period (AERP) measured using programmed electrical 
stimulation (PES) with (A) 100 ms and (B) 150 ms drive trains in rats exposed to IH 
or normoxic conditions for 7 days.  AERP was measured in both the high-right atrium 
(HRA) and mid-right atrium (MRA). Values represent means ± SEM. **, P < 0.01; 
N.S, not significant. 
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Figure 3.13 Effect of intermittent hypoxia on atrial effective refractory period in 
the presence and absence of carbachol 
Atrial effective refractory period (AERP) measured using programmed electrical 
stimulation (PES) with (A, B) 100 ms (AERP100) and (C, D) 150 ms (AERP150) drive 
trains in rats exposed to IH or normoxic conditions for 7 days. AERP was measured 
in both the high-right atrium (HRA; A, C) and mid-right atrium (MRA; B, D) in the 
absence (baseline) and presence of carbachol. Two-way ANOVA and Bonferroni’s 
multiple comparisons test revealed that carbachol significantly reduced AERP in all 
rats and that there was a significant interaction between drug and treatment on MRA 
ERP100 (B) and MRA ERP150 (D). Values represent means ± SEM. **, P < 0.01; ***, 
P < 0.001; N.S., not significant. 
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Figure 3.14 Effect of intermittent hypoxia on atrial effective refractory period in 
the presence and absence of atropine 
Atrial effective refractory period (AERP) measured using programmed electrical 
stimulation (PES) with a 100 ms drive train (AERP100) in rats exposed to IH or 
normoxic conditions for 7 days. AERP was measured in both the high-right atrium 
(HRA; A) and mid-right atrium (MRA; B) in the absence (pre-drug baseline) and 
presence of atropine. Pre-drug baseline values represent AERPs measured 
immediately before atropine injection, after a 60-minute washout period for 
carbachol. Atropine prolonged ERP at both atrial sites in all rats. Values represent 
means ± SEM. **, P < 0.01; N.S., not significant. 
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Table 3.2: Right atrial effective refractory periods (in ms) rats exposed to 7 
days of IH or normoxia measured in the presence and absence of carbachol, 
atropine, darifenacin, isoproterenol and propranolol.  
 
 
 
Values are means ± SEM; n, number of rats. HRA ERP, high-right atrial effective 
refractory period; MRA ERP, mid-right atrial effective refractory period. The 
subscripts 100 and 150 indicate basic drive cycle lengths of 100 ms and 150 ms, 
respectively. *, P < 0.05; †, P < 0.01 for intermittent hypoxia-exposed rats compared 
to normoxic controls within each drug group. ‡, significant interaction effect (P < 
0.05) between drug and treatment. 
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determine the role of the M3 receptor in modulating AERP in IH and normoxia- 
exposed rats. We found that darifenacin caused similar increases in AERP in both 
groups (AERP increased by about 14 ms in IH-exposed rats and by 11 ms in 
normoxic control rats; Figure 3.15), suggesting similar contributions of the M3 
receptor to AERP in the two groups. The nonselective β-adrenergic receptor agonist 
isoproterenol reduced AERP of the MRA from 41 ± 3 to 33 ± 2 in normoxic animals 
and from 41 ± 4 to 35 ± 3 in IH-exposed rats (Figure 3.16). Two-way ANOVA 
revealed a significant interaction between drug (isoproterenol) and treatment, 
suggesting that IH-exposed animals may be less sensitive to isoproterenol (Figure 
3.16; Table 3.2). Figure 3.17 shows that treatment with the nonselective β-
adrenergic receptor antagonist propranolol resulted in significantly longer AERPs in 
animals exposed to IH compared to normoxic control rats in both high (P < 0.01) and 
mid-right atrial sites (P < 0.05). Since AERPs were not significantly different prior to 
propranolol administration, this suggests that the effects of propranolol were greater 
in IH-exposed rats, possibly as a result of increased basal adrenergic activation. 
 
3.7 Atrial fibrillation inducibility and effects of autonomic receptor drugs 
Atrial burst pacing (Figure 3.18A) and PES (Figure 3.19) induced atrial 
arrhythmias with features that define AF: rapid, chaotic atrial activation patterns and 
irregularly irregular ventricular responses. All atrial arrhythmias with these 
characteristics were labelled as AF in this study, although a true diagnosis of AF 
requires high density mapping techniques and recording from both left and right atria 
(Tuomi et al., 2010). In normoxia-exposed control animals, AF was not inducible with 
PES (0 of 27, 0%). Burst pacing is a more provocative stimulus for arrhythmia  
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Figure 3.15 Effect of intermittent hypoxia on atrial effective refractory period in 
the presence and absence of darifenacin 
Atrial effective refractory period (AERP) measured using programmed electrical 
stimulation (PES) with (A, B) 100 ms (AERP100) and (C, D) 150 ms (AERP150) drive 
trains in rats exposed to IH or normoxic conditions for 7 days. AERP was measured 
in both the high-right atrium (HRA; A, C) and mid-right atrium (MRA; B, D) in the 
absence (pre-drug baseline) and presence of darifenacin. Pre-drug baseline AERPs 
were measured immediately before darifenacin injection, following a 60-minute 
washout period for carbachol. Two-way ANOVA and Bonferroni’s multiple 
comparisons test revealed that darifenacin prolonged ERP at both atrial sites in all 
rats. Values represent means ± SEM. **, P < 0.01; N.S., not significant. 
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Figure 3.16 Effect of intermittent hypoxia on atrial effective refractory period in 
the presence and absence of isoproterenol 
Atrial effective refractory period (AERP) measured in the high-right atrium (HRA; A) 
and mid-right atrium (MRA; B) in the absence (baseline) and presence of 
isoproterenol using programmed electrical stimulation (PES) with a 100 ms drive 
train (AERP100) in rats exposed to IH or normoxic conditions for 7 days. Two-way 
ANOVA and Bonferroni’s multiple comparisons test revealed that isoproterenol 
shortened ERP of the HRA (A) in normoxic, but not in IH rats, and there was a 
significant drug and treatment interaction in both high (A) and mid (B) right atrial 
sites. Values represent means ± SEM. *, P < 0.05; ***, P < 0.001; N.S., not 
significant. 
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Figure 3.17 Effect of intermittent hypoxia on atrial effective refractory period in 
the presence and absence of propranolol 
Atrial effective refractory period (AERP) measured using programmed electrical 
stimulation (PES) with a 100 ms drive train (AERP100) in rats exposed to IH or 
normoxic conditions for 7 days. AERP was measured in the high-right atrium (HRA; 
A) and mid-right atrium (MRA; B) in the absence (pre-drug baseline) and presence 
of propranolol. Pre-drug baseline values represent the AERP measured immediately 
before propranolol administration, following a 40-minute washout period for 
isoproterenol. Propranolol prolonged ERP of the MRA in IH, but not in normoxic rats 
(B). Values represent means ± SEM. *, P < 0.05; **, P < 0.01; N.S., not significant. 
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Figure 3.18 AF induction with atrial burst pacing 
(A) Characteristic burst-induced atrial fibrillation (AF) in a rat exposed to 7 days of 
IH. Note the absence of P-waves and the irregular QRS responses on limb lead 1 
(LL1), and the rapid, irregular atrial activation patterns and fractionation on the intra-
atrial electrograms (LRA, low-right atrium; MRA, mid-right atrium; HRA, high-right 
atrium). (B) For comparison, a representative recording of failure to induce AF with 
burst pacing in a 7 day normoxia-exposed rat.  
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Figure 3.19 Characteristic recording of AF induced by PES 
Characteristic recording of atrial fibrillation (AF) induced by programmed electrical 
stimulation (PES) with a single extrastimulus (S2) in a rat exposed to 7 days of IH. 
Note the rapid, irregular atrial activation patterns on the intra-atrial electrograms 
(LRA, low-right atrium; MRA, mid-right atrium; HRA, high-right atrium), in particular 
the different tachycardia rates in HRA compared to MRA and LRA. Irregularly 
irregular ventricular responses and the absence of P-waves can be seen on limb 
lead 1 (LL 1). Susceptibility to PES-induced AF indicates that IH-exposed rats have 
a highly vulnerable atrial substrate. Normoxia exposed rats were completely 
insensitive to arrhythmia induction with PES. 
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induction, but induced AF in only 4 of 27 (15%) normoxia-exposed rats. In contrast, 
IH-exposed rats were quite sensitive to AF induction with burst pacing (14 of 27, 
52%) and were moderately susceptible to AF induction with PES (7 of 27, 26%). Chi-
squared analysis revealed that IH-exposed rats were more sensitive to AF induction 
with both PES (P < 0.01; Figure 3.20) and burst pacing (P < 0.01; Figure 3.20) 
compared to normoxic controls. All rats that were susceptible to AF induction had 
short-lived, nonsustained AF (<10 seconds), with the exception of two rats in the IH 
group that were highly susceptible to PES-induced AF. One rat consistently had self-
terminating AF episodes lasting approximately 3 minutes on average; the other 
remained in sustained AF for over an hour until exogenous termination was 
attempted with injection of atropine (1 mg/ml, i.p.).  
Previous studies have used carbachol to enhance AF inducibility and duration 
(Tuomi et al., 2011; Tuomi et al., 2010) but surprisingly, carbachol did not 
significantly affect AF susceptibility in normoxia-exposed rats with either PES (0/13 
without versus 0/13 with carbachol; Figure 3.21A) or burst pacing (1/13 without 
versus 2/13 with carbachol; Figure 3.21A). On the other hand, in IH-exposed rats 
carbachol significantly increased susceptibility to burst-induced AF (from 5/13 at 
baseline to 10/13 with carbachol, P < 0.05; Figure 3.21A). Carbachol increased the 
number of IH-exposed rats that were susceptible to AF induced by PES (2/13 
without carbachol versus 6/13 with carbachol, P = 0.089; Figure 3.21A) but this 
difference was not statistically significant. Muscarinic receptor blockade with atropine 
completely prevented AF inducibility in IH-exposed rats with both PES (P = 0.055; 
Figure 3.21B) and burst pacing (P < 0.001; Figure 3.21B). Darifenacin also 
prevented AF inducibility in all IH rats with both pacing modalities (Figure 3.21C), but  
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Figure 3.20 Effect of intermittent hypoxia on the inducibility of AF using 
different methods of stimulation 
Incidence of AF induced with programmed electrical stimulation (PES) or burst 
bacing (burst) in rats exposed to IH or normoxic conditions for 7 days. IH increased 
susceptibility to AF induction with both pacing modalities compared to normoxic 
controls. **, P < 0.01.  
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Figure 3.21 Effect of muscarinic receptor drugs on AF inducibility  
Incidence of AF induced with programmed electrical stimulation (PES) or burst 
bacing (burst) in rats exposed to IH or normoxic conditions for 7 days in the 
presence and absence of carbachol (A), atropine (B) or darifenacin (C). In IH-
exposed rats with burst pacing, carbachol enhanced susceptibility to AF induction 
and atropine completely prevented inducibility of AF. *, P < 0.05; ***, P < 0.001; 
N.S., not significant.  
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Figure 3.22 Effect of adrenergic drugs on AF inducibility 
Incidence of AF induced with programmed electrical stimulation (PES) or burst 
bacing (burst) in rats exposed to IH or normoxic conditions for 7 days in the 
presence and absence of isoproterenol (A) or propranolol (B). Isoproterenol 
significantly increased susceptibility to AF induction with burst pacing in normoxic 
rats but had no effect on AF susceptibility in IH-exposed rats with either pacing 
method. *, P < 0.05; N.S., not significant.  
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these differences were not statistically significant. Interestingly, isoproterenol 
significantly increased susceptibility to AF induction with burst pacing in normoxic 
rats (P < 0.05; Figure 3.22A) but had no effect on AF susceptibility in IH-exposed 
rats with either pacing method (Figure 3.22A). In IH-exposed rats, β-adrenergic 
receptor blockade with propranolol reduced the incidence of AF induced by PES (P 
= 0.121) and burst pacing (P = 0.074; Figure 3.22B) but these differences were not 
stastically significant. Propranolol also prevented AF induction with burst pacing in 
one of the normoxia-exposed rats (reduced the incidence of AF from 3/9 to 2/9; P = 
0.510; Figure 3.22B). 
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4.1 Overview 
This study, to our knowledge, is the first to demonstrate AF promotion in an 
animal model of OSA, using IH alone to mimic obstructive apneas. This matches the 
enhanced AF susceptibility seen in OSA patients and, for the first time, 
demonstrates a role for IH in atrial arrhythmogenesis. We found substantially 
enhanced AF vulnerability in IH-exposed rats compared to control animals exposed 
to normoxic conditions using both PES and burst pacing to induce AF. Susceptibility 
to AF induction with PES indicates that IH rats have a highly vulnerable atrial 
substrate; on the other hand, control animals were insensitive to PES-induced AF. 
We investigated the underlying pathological determinants of the AF-promoting 
substrate and identified a number of atrial substrate changes that have not been 
reported previously in an IH model of OSA, including (1) lowered atrial Cx 43 
content, (2) heightened cholinergic sensitivity with increased muscarinic receptor 
protein expression and (3) alterations in adrenergic function characterized by 
enhanced responses to propranolol and blunted responses to isoproterenol. 
Atropine completely prevented AF inducibility, and the sensitivity to carbachol-
induced AF was enhanced, in IH-exposed rats, indicating that parasympathetics 
were critical for AF inducibility. Adrenergic activation also played a role, since 
propranolol prevented burst-induced arrhythmias in a third of IH-exposed rats that 
were inducible at baseline. These findings highlight a causal role for chronic IH in 
OSA-related AF susceptibility and in the formation of AF-promoting vulnerable 
substrates. 
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4.2 Considerations of the model 
The first overarching aim of this thesis was to establish that an IH model of 
OSA had enhanced AF inducibility to facilitate investigation of the underlying 
vulnerable substrates. We used an IH regimen composed of repeated 80-second 
cycles of hypoxia alternated with 120-second cycles of normoxia, resulting in 
exposure of rats to 18 events per hour, thereby emulating a moderate form of OSA 
based on the AHI (AASM Task force, 1999). The IH stimulus was applied for 8 hours 
per day, during the diurnal sleep period of the rat, and based on behavioural 
assessment, our rats slept normally during this time, with the polyphasic pattern 
characteristic of rats (Simasko and Mukherjee, 2009). Specifically, rats appeared to 
be sleeping for most of the exposure duration, with the exception of microarousals 
typically observed in laboratory conditions (for example, 396 wake-ups on average in 
a 12 hour diurnal period; Clancy et al., 1978). In IH rats, respiration rate increased 
during phases of hypoxia, which was not due to hypercapnia since eucapnic 
conditions were maintained within the chambers. This observation is an indication 
that the fractional inspired O2 within the chambers was producing intermittent 
hypoxemia, since hypoxia in the blood induces hyperventilation (Bisgard and 
Neubauer, 1995). Overall, this suggests that our results were due to IH.    
  The usefulness of our IH model of OSA can be understood from previously 
reported characteristics (Moreau and Ciriello, 2013, 2015) and an appreciation of the 
critical pathophysiological role of IH, enabled by over two decades of OSA research 
using numerous variants of the basic paradigm. Earlier studies have demonstrated 
that our IH model displays many features of human OSA, including significant 
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alterations in body energy balance (Moreau and Ciriello, 2013) as well as blood 
pressure elevation and reduced baroreflex gain with 95-day exposures, indicating 
substantial cardiovascular dysfunction (Moreau and Ciriello, 2015). Studies of 
laboratory rodents subjected to diurnal IH are the most frequently used OSA 
paradigm, even though rodents do not experience the intrathoracic pressure swings 
or hypercapnea (Fletcher et al., 1992a) that occur in OSA patients during apnea (for 
review, see Dempsey et al., 2010). The focus on IH is based on the hypothesis 
(Dematteis, 2009) that among the three pathophysiological components of OSA, IH 
is the most important in the development of cardiovascular complications. Indeed, IH 
by itself generates sympathetic hyperactivity (Gonzalez-Martin et al., 2009; Zoccal et 
al., 2008) and hypertension (Allahdadi et al., 2008; Zoccal et al., 2008; Zoccal et al., 
2007) in experimental animals. Thus, although our model does not include all 
attributes of human OSA, our findings provide important lessons for understanding 
the human counterpart and address previously unanswered questions about the role 
of IH in atrial arrhythmogenesis. 
 
4.3 Principal findings 
Although IH has been used extensively to study numerous OSA-related 
comorbidities, this study is the first to examine the effects of an IH model on atrial 
arrhythmia susceptibility. We found that repeated bouts of IH, as occur due to OSA, 
are sufficient to significantly enhance AF susceptibility after just 7 days. Two 
different pacing protocols were used to identify AF susceptibility: PES with a single 
extrastimulus and atrial burst pacing. PES is thought to initiate AF as it occurs 
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physiologically, since AF episodes are often preceeded by premature atrial beats 
(Hoffman et al., 2006). On the other hand, atrial burst pacing more reliably induces 
AF by promoting cardiac electrical instability (Jones et al., 2008). Susceptibility to AF 
induced by PES was previously not reported in the rat, but in other small animals 
such as wild-type mice, AF is rarely induced by PES with a single extrastimulus 
(Tuomi et al., 2010). Thus, it was expected to be similarly non-inducing in the rat. 
Indeed, we found that AF could not be induced with PES in normoxia-exposed 
control rats (0%, 0/27), but IH exposure significantly increased AF inducibility with 
PES (26%, 7/27, P < 0.01). Susceptibility to AF induction with PES indicates that IH-
exposed rats possess a highly vulnerable atrial substrate, demonstrating the 
profound effect and early latency of chronic IH during the sleep period, as it occurs 
in OSA of moderate severity.  
Since PES is thought to more readily induce re-entry than triggered activity 
(Jalife et al., 2009), PES-induced AF susceptibility suggests a re-entrant mechanism 
underlying the enhanced atrial arrhythmias in IH rats. This is supported by the fact 
that AF was more readily induced in the MRA, where AERP was significantly shorter 
than in the HRA since myocardial regions with shorter refractory periods (Jalife et 
al., 2009) and enhanced spatial dispersion of refractoriness (Allessie et al., 1976) 
are more vulnerable to reentry. These observations are important because they are 
consistent with recent studies demonstrating significantly diseased reentry 
substrates in the atria of OSA patients (Dimitri et al., 2012). Compared to patients 
with AF only, those with both OSA and AF demonstrate site-specific conduction 
abnormalities, areas of low voltage and regions of electrical silence, suggesting 
underlying conduction dissociation, with no difference in refractory period at rest 
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(Dimitri et al., 2012). In this study, highly variable activation patterns were recorded 
simultaneously from high and mid-right atrial sites during AF, indicating areas of 
conduction block and underlying structural and/or electrical heterogeneities, 
consistent with OSA patients. This observation also provides further support for 
reentry, since activation heterogeneities and areas of conduction block are key 
determinants underlying the initiation of reentry in the right atrium in particular 
(Aslanidi et al., 2009). Moreover, substrate vulnerability in our IH rats was not due to 
lowering of AERP in the resting state, similar to OSA patients (Dimitri et al., 2012). 
Taken together, this suggests that the electrophysiological substrate in our IH rats 
resembles that found in OSA patients. 
Having successfully established an IH model of OSA-related AF promotion, 
the remaining objectives of this thesis were to investigate the responsible underlying 
vulnerable substrates. We noted a number of atrial substrate changes that may 
serve as pathological determinants of AF susceptibility; however, parasympathetic 
activation was found to be particularly important for AF promotion in our model. 
Atropine consistently suppressed AF inducibility in IH-exposed rats. Moreover, IH-
exposed rats had significantly enhanced sensitivity to AF induction in the presence 
of carbachol with both PES and burst pacing, similar to models of AF associated 
with enhanced cardiac parasympathetic function (Guasch et al., 2013; Tuomi et al., 
2010). Very little is known of the effects of chronic IH on atrial parasympathetic 
function, so we used muscarinic receptor agonist and antagonist drugs as tools to 
identify potential changes in the atrial cholinergic responses to stimulation and 
antagonism. Cholinergic enhancement may be due to (1) an increase in 
parasympathetic activation of the myocardium, either from elevated vagal tone or as 
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a result of changes in local circuit neurons of the ICANS, or (2) increased cholinergic 
sensitivity at the end-organ level. From the findings of this thesis, IH-exposed rats 
had significantly enhanced responses to cholinergic stimulation with carbachol 
compared to normoxic controls with no difference in sensitivity to muscarinic 
receptor blockade with atropine between the two groups. These results can be 
interpreted to mean that, while not affecting the resting level of cholinergic activation, 
IH exposure augments cholinergic sensitivity. This was probably at least partially 
due to an increase in muscarinic receptor number, since we found significantly 
higher atrial M2 muscarinic receptor protein in 7 day IH-exposed rats. Given the 
ability of atropine to prevent AF induction and the higher incidence of carbachol-
induced arrhythmias in the IH group, this enhanced cholinergic sensitivity likely 
contributed significantly to the enhanced AF susceptibility we observed in these 
animals. Studies of transgenic mice have shown that both enhanced M2 (Posokova 
et al., 2013; Guasch et al., 2013) and M3 (Tuomi et al., 2010) receptor function in 
the atria are associated with enhanced susceptibility to electrically-induced AF, 
which is consistent with the current data. In these models, cholinergic enhancement 
was due to a lack of RGS proteins, which normally limit muscarinic receptor 
signalling. In addition to the increase in atrial muscarinic receptor protein content 
that we observed, it is possible that reductions in RGS proteins may also play a role 
in the enhanced cholinergic responses and carbachol-induced AF susceptibility. 
Characterizing changes in RGS protein expression in our model would be an 
interesting experiment for future study. 
The enhanced cholinergic sensitivity we observed is a very interesting and 
novel finding, and may have implications for earlier reports that chronic IH 
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attenuates baroreflex control of the heart rate but enhances heart rate responses to 
vagal stimulation (Lin et al., 2007; Gu et al., 2007). These observations could be 
explained by our findings, although relatively long exposure lengths in these studies 
and differences in methodology make extrapolation of our findings to theirs difficult. 
In addition to cholinergic enhancement, we used pharmacological tools to 
identify novel changes in atrial adrenergic function in the IH-exposed rats, which 
agree with and extend observations from previous models of IH. After 7 days, we 
observed enhanced responses to adrenergic receptor blockade with propranolol in 
IH-exposed rats compared to normoxic controls. This effect is likely a reflection of an 
increase in baseline adrenergic receptor activation due to IH-mediated potentiation 
of sympathetic outflow (Dick et al., 2007; Xing and Pilowsky, 2010). Although we did 
not record nerve activity, previous studies have shown that IH augments tonic 
sympathetic nerve activity beginning during the first day of IH exposure (Dick et al., 
2007; Xing and Pilowsky, 2010). With increasingly chronic exposures, the 
manifestations of IH-induced sympathetic potentiation mirror those seen in OSA 
patients (Narkiewicz et al., 1999; Carlson et al., 1996; Narkiewicz et al., 1998; 
Sajkov et al., 1994), including elevated plasma catecholamines (Gonzalez-Martin et 
al., 2009), increased tonic sympathetic nerve firing (Zoccal et al., 2007, 2008), 
increased chemoreflex control of sympathetic activity (Braga et al., 2006; Huang et 
al., 2009) and the loss of baroreflex control of sympathetic activity (Yamamoto et al., 
2013), all of which result in hypertension. Elevated plasma catecholamines 
(Gonzalez-Martin et al., 2009) and increased sympathetic nerve activity (Zoccal et 
al., 2007, 2008) have been reported as early as day 8 and 15 of IH exposure, 
respectively, and blood pressure elevation can occur as early as day 7 or 8 (Fletcher 
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et al., 1999; Sica et al., 2000). More recently, chronic radiotelemetry studies indicate 
that MAP is significantly increased during both day and night by the third day of IH 
exposure and continues to rise until day 7, with concomitant loss of baroreflex 
control of sympathetic activity (Yamamoto et al., 2013). These studies suggest that 
the enhanced responses to propranolol we observed at day 7 were due to early 
sympathetic potentiation.  
Early potentiation of sympathetic activity may also explain the blunted 
responses to adrenergic receptor stimulation with isoproterenol observed in IH-
exposed rats. Although speculative, IH-mediated sympathetic enhancement may 
cause functional agonist-dependent adrenergic receptor desensitization that 
underlies the isoproterenol insensitivity. As sympathetic activation becomes more 
severe with increasingly chronic exposures, desensitization may also occur in the 
form of reduced adrenergic receptor levels, such as that which occurs due to 
sympathetic overactivity caused by heart failure (Bristow et al., 1982, Ihl-Vahl et al., 
1996) or aging (White et al., 1994). This would also explain the reduction in β-
adrenergic receptor content we observed in 95-day IH-exposed rats. We recognize 
that further studies, including evaluation of sympathetic tone and radioligand 
assessment of receptor function, are required to explore these possibilities. 
Activation of sympathetic activity appeared to be less important for AF 
promotion than parasympathetic influences in our model. Adrenergic blockade with 
propranolol was modestly effective at reducing the incidence of AF in IH-exposed 
rats compared to baseline levels, but these differences did not reach statistical 
significance. In contrast, atropine abolished AF inducibility in all IH-exposed rats, 
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lowering the incidence of AF from 38% to 0% with PES (P = 0.055) and from 63% to 
0% with burst pacing (P = 0.007). It is recognized that differences between the ability 
of atropine and propranolol to prevent AF are dose-dependent, and that a relatively 
high dose of atropine or a low dose of propranolol, compared to ED50 values, could 
explain this effect. Dose-response curves were ascertained in pilot studies (see 
appendices), and doses of 1.0 mg/kg (i.p.) atropine and 10 mg/kg (i.p.) propranolol 
were selected, as they similarly increased heart rate by approximately 25%. In 
addition, the 1.0 mg/kg dose we used for atropine is farther from the LD50 reported in 
the literature for the rat (280 mg/kg; Cahen and Tvede, 1952) than the chosen 10 
mg/kg dose of propranolol is from the corresponding LD50 of propranolol in the rat 
(76 mg/kg i.p.; RTECS, 2015). Overall, this suggests that parasympathetic activation 
was more important than sympathetic activation for AF inducibility in IH-exposed 
animals. Similar findings have been reported in a study that investigated the 
mechanisms of enhanced AF inducibility during individual episodes of simulated 
apnea in pigs (Linz et al., 2012). In this study, AF inducibility was significantly 
attenuated by atropine while renal sympathetic denervation had a more modest 
effect and atenolol did not significantly reduce AF susceptibility.  
IH-exposed rats exhibited significant reductions in Cx 43 content in the atria, 
which may contribute to the electrophysiological substrate underlying enhanced 
arrhythmias in our model. Although we didn’t use pharmacological tests to 
demonstrate the importance of Cx 43 for AF inducibility as we did with the autonomic 
receptors, there is considerable evidence that reductions in Cx 43 can promote AF. 
In AF patients, loss of function Cx 43 mutations associated with reduced gap 
junctional coupling have been reported (Thibodeau et al., 2010) and reduced Cx 43 
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levels are found in chronic AF patients (Kostin et al., 2002) and animal models of 
AF, while restoring Cx 43 can prevent AF inducibility (Igarashi et al., 2012). In an 
earlier study, our lab used the same pacing protocols employed in this thesis to 
show that reduced Cx 43 content was associated with enhanced AF susceptibility in 
a genetic mouse model of Oculodentodigital dysplasia (ODDD) (Tuomi et al., 2011). 
Although the ODDD model is associated with a more significant reduction of total 
atrial Cx 43 protein content (60%; Manias et al., 2008) than what we observed in our 
IH rats (25% reduction in IH versus normoxic rats at 7 days), it is still likely that IH-
induced Cx 43 lowering contributed to AF susceptibility if one considers a threshold 
model of arrhythmogenesis, which recognizes that multiple physiological factors can 
produce the same electrophysiological outcome. The complex, heterogeneous 
pathophysiology of AF is well described by a threshold model as it involves multiple 
factors that contribute to substrate vulnerability. In this case, it can be concluded that 
reduced atrial Cx 43 contributed to substrate vulnerability to some extent, since it 
was present together with enhanced AF inducibility and its role is well established.  
Together with Cx 40, Cx 43 proteins comprise atrial gap junction channels, 
the subcellular structures that determine cardiac conduction velocity. As discussed 
in chapter 1, slow conduction velocity lowers the wavelength of re-entry circuits and 
facilitates AF maintenance, so a reduction in connexin expression would be 
expected to promote re-entry mechanisms that maintain AF. However, in strands of 
atrial myocytes from Cx 40-/- and Cx 43-/- mice, loss of Cx 43 reduces conduction 
velocity while loss of Cx 40 accelerates it (Beauchamp et al., 2006). Genetic models 
with reduced Cx 43 levels have enhanced AF susceptibility (Tuomi et al., 2011), 
while studies of Cx 40-/- mice have reported that AF inducibility was not different 
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from that of wild type mice (Schrickel et al., 2002) and that Cx40-/- were more 
resistant to AF induction in the presence of carbachol (Tuomi et al., 2011). Here, we 
found that Cx 43 protein and mRNA were significantly lower following 7 days of IH 
compared to normoxic controls and at day 95 of IH, Cx 43 mRNA was also lower in 
IH-exposed rats compared to normoxic controls, demonstrating sustained Cx 43 
reductions induced by IH. Corresponding protein levels were not measured at the 95 
day point. On the other hand, levels of Cx 40 mRNA and protein were not different in 
IH and normoxia-exposed rats at any of exposure lengths examined. Given the roles 
of the dominant atrial connexin isoforms in AF promotion, the lowering of Cx 43 and 
lack of change in Cx 40 we observed at day 7 in IH-exposed rats is consistent with 
the increased AF vulnerability in these animals. 
When studies began, there were no published papers demonstrating 
enhanced AF susceptibility in an animal model of OSA. Recently, Iwasaki et al. 
(2014) were the first to publish findings of enhanced atrial arrhythmia inducibility in a 
long-term OSA paradigm, which mimicked apneas by intermittently closing the 
airways of intubated rats. Our findings of connexin remodelling agree with, and shed 
light on, the results of Iwasaki’s study. Consistent with our data, enhanced AF 
vulnerability was accompanied by reductions in atrial Cx 43 protein, along with 
significant atrial conduction slowing, as has been recently observed in OSA patients. 
Our data suggest that IH is at least partially responsible for these observations since 
we observed similar lowering of Cx 43 using IH alone rather than repetitive airway 
obstructions to mimic OSA.  
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4.4 Impact of research and implications 
Despite its clinical importance, the pathogenesis of OSA-related AF is poorly 
understood. Although IH has been used extensively to study numerous OSA-related 
comorbidities, this study is the first to examine the effects of a chronic model of IH 
alone on atrial arrhythmia susceptibility. One issue addressed by this thesis was to 
determine the role of the autonomic nervous system in AF susceptibility associated 
with chronic OSA, which was previously unknown. Researchers have primarily 
focused on role of autonomics in mediating the arrhythmogenic effects of individual 
episodes of simulated apnea or anoxia (Ghias et al., 2009; Linz et al., 2011; Linz et 
al., 2012; Iwasaki et al., 2012; Linz et al., 2013). Ghias et al. (2009) found that AF 
inducibility was increased during 2 minutes of anoxia in dogs, which was preventable 
with GP ablation or combined pharmacological blockade. In a pig model, Linz and 
colleagues demonstrated that enhanced AF inducibility during 2 minutes of 
simulated apnea could be abolished by atropine or vagotomy and reduced by renal 
sympathetic denervation (Linz et al., 2011; Linz et al., 2012). While useful for 
demonstrating the arrhythmogenic properties of acute apneic episodes and the 
prominent role of the autonomic nervous system, none of these models emulate 
chronic OSA, for which the enhanced risk of AF has been characterized.  
This work is the first to demonstrate the role of the autonomic nervous system 
in AF susceptibility in a chronic OSA model. Interestingly, in our chronic IH model of 
OSA, the parasympathetic nervous system was critical for AF promotion while the 
sympathetic nervous system appeared to be less important, paralleling that which 
occurs during simulated apneas (Linz et al., 2011; Linz et al., 2012). However, the 
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underlying mechanisms of chronic autonomic dysfunction with IH are very different 
from the acute surges of cardiac autonomic activation that occur with apneic 
episodes. For example, during acute apnea, enhanced cardiac vagal activation due 
to IH-mediated chemoreflex activation (Franchini and Krieger, 1993) likely explains 
the dependence of AF inducibility during apnea on parasympathetic activation (Linz 
et al., 2011; Linz et al., 2012), while our findings suggest that enhanced cholinergic 
sensitivity rather than enhanced vagal activation underlies parasympathetic 
enhancement with chronic IH exposure. At the same time, the role of sympathetic 
activity in contributing to AF susceptibility during acute apneas (Linz et al., 2012) is 
probably related to chemoreflex-mediated sympathetic activation (Franchini and 
Krieger, 1993), while chronic potentiation of sympathetic activity due to IH (Zoccal et 
al., 2007; Gonzalez-Martin et al., 2009) most likely contributes to modulating AF 
promotion in our model. Taken together with findings from acute apnea studies, our 
results point to a complex role for autonomic alterations in OSA-related AF 
pathophysiology, for the first time demonstrating long-term effects on atrial 
arrhythmogenesis.   
This thesis has also been the first to demonstrate a role for IH in OSA-related 
electrical remodelling. OSA patients exhibit slower atrial conduction velocities and 
prolonged atrial conduction times (Dimitri et al., 2012; Cagirci et al., 2011; Maeno et 
al., 2013a, 2015b), but it was previously unclear whether these alterations were due 
to OSA itself or a comorbid condition. The recent Iwasaki study described in section 
4.3 of this chapter represents the first published experimental evidence in support of 
the hypothesis that OSA itself causes AF-promoting electrical remodelling. This 
thesis, with the findings of reduced Cx 43 content associated with enhanced AF 
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vulnerability, sensitivity to PES induction and activation heterogeneities in the right 
atrium, has provided additional experimental support for that hypothesis, as well as 
additional insights into the underlying mechanisms, highlighting IH as a critical 
factor. Further studies are needed to characterize the conduction characteristics of 
our IH model of OSA. 
Based on our results and those of previous studies, I propose the following 
model for OSA-related AF pathophysiology. During apnea, the atria become 
vulnerable to AF primarily as a result of cardiac vagal outflow associated with 
peripheral chemoreceptor stimulation by hypoxia (Franchini and Krieger, 1993; 
Boscan et al., 2001). Activation of the chemoreceptors also augments sympathetic 
activity (Franchini and Krieger, 1993; Boscan et al., 2001), which contributes to AF 
vulnerability to a lesser extent (Linz et al., 2011), while the resultant blood pressure 
surges activate the baroreflex to further augment cardiac vagal tone and put the 
breaks on sympathetic flow (Braga et al., 2007). Over time, chronic exposure to IH 
during the sleep period leads to formation of a highly vulnerable atrial substrate, as 
indicated by susceptibility to PES-induced AF in IH-exposed rats. This substrate 
persists after the sleep period in the absence of apneas, explaining the enhanced 
risk of AF in awake OSA patients. Parasympathetic enhancement, characterized by 
increased cholinergic sensitivity, is the principal mediator of chronically enhanced AF 
vulnerability. However, through enhancement of chemoreceptor sensitivity (Braga et 
al., 2006; Huang et al., 2009) and the attenuation of baroreflex control of 
sympathetic activity (Yamamato et al., 2013) chronic IH leads to sympathoadrenal 
activation (Gonzalez-Martin et al., 2009; Zoccal et al., 2007, 2008; Peng et al., 
2014), chronic IH augments sympathetic activity, which also contributes to AF 
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susceptibility. Substrate vulnerability is further enhanced by IH-induced lowering of 
Cx 43 levels, potentially due to reductions in atrial conduction velocity, as has been 
found in association with reduced connexin 43 levels in a model of OSA induced by 
repetitive trachel occlusions (Iwasaki et al., 2014). By reducing the wavelength, slow 
conduction velocity favours re-entrant mechanisms of AF maintenance, consistent 
with the present data.  
 In addition to providing novel pathophysiological insights, our findings have 
clinically significant implications. Despite the wealth of epidemiological data in 
support of a causal relationship between OSA and AF (Kanagala et al., 2003; Fein et 
al., 2013), animal models are important in order to determine causality and explore 
underlying mechanisms in the absence of confounding factors present in clinical 
databases. We demonstrated that IH alone substantially enhances AF susceptibility 
and induces a highly vulnerable atrial substrate that includes right atrial activation 
heterogeneities, connexin remodelling and both cholinergic and adrenergic 
dysfunction. Thus, exposure to chronic IH and its sequalae may contribute to the 
greater risk of procedural failure seen in OSA patients (Ng et al., 2011). The 
dependence of enhanced AF susceptibility on autonomic influences in our IH rats 
highlights the potential importance of combining standard ablation approaches with 
adjunctive procedures that target the ANS, such as GP ablation (Katritsis et al., 
2013), for successful treatment of AF in OSA patients.   
Importantly, we found that enhanced AF susceptibility and vulnerable 
substrate formation were evident after just 7 days of a moderate IH stimulus. This 
highlights the fact that the latency of the onset of arrhythmogenesis in OSA may be 
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shorter than previous studies have suggested (Iwasaki et al., 2014). The feasibility of 
therapies targeted at OSA for reducing the arrhythmia burden has been 
demonstrated (Fein et al., 2013; Kanagala et al., 2003). Given the mechanistic link 
and potentially short latency of AF onset demonstrated by this thesis, early 
identification and treatment of OSA may be critical to prevent the progressive 
worsening of AF due to remodelling. OSA is extremely common, found in 17-26% of 
men and 9-28% of women (Young et al., 1993) and yet, the true burden of OSA is 
likely underestimated since over 85% of patients remain undiagnosed (Young et al., 
1997; Kapur et al., 2002). We have shown that AF-promoting mechanisms are 
initiated within days by IH alone, which could mean that in many undiagnosed OSA 
patients, the process of arrhythmogenesis has already begun. Clearly, the need for 
improved screening and/or diagnostic methods in order to identify OSA in its early 
stages is a significant clinical problem.  
 
4.5 Limitations and future studies 
Like all animal models of human disease, the one we used here has 
limitations. As discussed in section 4.2 of this chapter, OSA models with IH alone 
have become a gold standard in the field of OSA-related cardiovascular disease 
research even though they do not mimic the alterations in intrathoracic pressure and 
hypercapnea (Fletcher et al., 1992a) experienced by OSA patients during each 
episode of apnea (Dempsey et al., 2010). This is because IH by itself produces the 
autonomic and cardiovascular alterations caused by OSA, which has led to the 
conclusion that IH is the most important pathophysiological component (For review, 
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see Dematteis, 2009). Thus, although our IH stimulus does not capture all aspects of 
the apneic insults as they occur in OSA patients, our findings provide important 
lessons for understanding the human counterpart. Clinical investigation is needed to 
validate the applicability of our findings to humans. 
In OSA, hypoxia in the lungs during apnea results in lowering of the partial 
pressure of oxygen in the blood, which in turn causes chemoreflex activation. During 
phases of hypoxia, we exposed rats to fractional inspired oxygen concentrations of 
6.5-7%, but did not measure the resultant arterial hypoxemia. However, based on 
visual assessment, respiration rate appeared to increase rapidly during phases of 
hypoxia, which was not due to hypercapnia since eucapnic conditions were 
maintained within the chambers. This observation is an indication that the 6.5-7% 
FiO2 was producing hypoxemia, since hypoxia in the blood induces ventilation 
(Bisgard and Neubauer, 1995). In an earlier study that used an IH regime and 
apparatus similar to ours to model IH in the rat, a more modest lowering of the 
inhaled oxygen fraction to 10% during the hypoxic phase produced significant 
reductions in arterial blood oxygen levels (from 97 mmHg during normoxia to 57 
mmHg during hypoxia; nadir HbO2 86.3%) and hyperventilation (Gonzalez-Martin et 
al., 2009), as was observed in our rats. Overall, this suggests that our IH stimulus 
induces hypoxemia, but further studies should be performed in our lab in order to 
validate and quantify the cyclic changes in oxygen saturation in our model.   
Sympathetic activity should also be assessed in future studies. The enhanced 
responses to adrenergic receptor blockade we observed in IH-exposed rats is an 
indication of increased activation of adrenergic receptors but measurements of 
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plasma catecholamines or sympathetic nerve activity are required to determine 
whether 7 days of exposure to our IH model increases overall sympathetic activity. 
Although previous studies employing similar IH models have demonstrated blood 
pressure elevation following 7 days of IH exposure (Fletcher et al., 1999; Sica et al., 
2000) and significantly elevated plasma catecholamines as early as day 8 
(Gonzalez-Martin et al., 2009), subtle differences in methodology introduce problems 
for extrapolating these findings to our model.  
We attempted to quantify connexins and autonomic receptor protein levels 
with western blotting in 95 day IH- and normoxia-exposed rats, but were 
unsuccessful because of sample degradation as a result of freezer break-down. 
Therefore, our findings of lower β-adrenergic receptors and Cx 43 in 95 day IH-
exposed rats are based solely on mRNA expression, which does not always 
correlate with protein expression. In addition, we used overall mRNA and protein 
content as an index for connexin dysfunction, but remodelling can also occur at the 
level of connexin phosphorylation status or changes in distribution. Connexin 
function also depends on intracellular pH, Ca2+ and protein-protein interactions, none 
of which were assessed in this study. For adrenergic and muscarinic receptors, we 
examined mRNA and protein expression and used atrial responses to receptor 
agonist and antagonist drugs as physiologically relevant indices of receptor function. 
However, we did not explore potential changes in components of the associated 
intracellular signalling cascades, which would be an interesting issue for future 
study.   
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The novel findings in this thesis provide rationale for further experiments. With 
the new knowledge that our IH model leads to reductions in atrial Cx 43 content and 
right atrial activation heterogeneities associated with AF vulnerability, characterizing 
the conduction characteristics in our model is an important experiment for future 
study. Since pharmacological blockade prevented AF inducibility, a logical next step 
would be to demonstrate whether an analogous clinically relevant procedure, such 
as GP ablation, produces the same effects. It was recently demonstrated that carotid 
body ablation prevents the sympathoadrenal activation and hypertension induced by 
chronic IH In rats (Peng et al., 2014). Given the central importance of peripheral 
chemoreceptors in mediating the autonomic effects of IH, it would be worthwhile to 
investigate whether chemoreceptor destruction with carotid body ablation could 
ameliorate the enhanced AF vulnerability and autonomic alterations demonstrated in 
this study. Finally, to determine how the AF-promoting substrate advances with time, 
our studies should be repeated in rats subjected to longer IH exposures; perhaps 
two or three weeks at first, and eventually, 95 days to observe extremely chronic 
effects.  
 
4.6 Summary 
For the first time, we demonstrated AF promotion in an IH model of OSA. 
After just 7 days of diurnal exposure to chronic IH, a highly vulnerable atrial 
substrate forms, evidenced by susceptibility to PES-induced AF in IH-exposed rats. 
Enhanced arrhythmia susceptibility was accompanied by atrial substrate changes 
including cholinergic enhancement, autonomic imbalance, and connexin 
remodelling. Cholinergic enhancement was particularly important. These findings 
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provide novel insights into the mechanisms underlying OSA-related AF and the 
formation of vulnerable substrates, highlighting a causal role for IH, and a novel 
model for further exploration of the underlying mechanisms. Addressing these 
mechanisms may provide novel therapeutic targets for AF in OSA patients, the need 
for which will become increasingly important as the prevalence of OSA increases 
with the aging of the population (Duran et al., 2001; Young et al., 2004). 
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Appendix 1 – Dose-response curves of autonomic receptor drugs 
 
Figure 1 Negative chronotropic effects of cumulative doses of carbachol (CCh) 
administered intraperitoneally in an adult, male Sprague-Dawley rat. Heart rate (HR) 
at each dose is given as the percent of the steady-state baseline value immediately 
before that dose. Values represent maximal responses. 
 
Figure 2 Positive chronotropic effects of cumulative doses of atropine administered 
intraperitoneally in an adult, male Sprague-Dawley rat. Heart rate (HR) at each dose 
is given as the percent increase from the steady-state baseline value immediately 
before that dose. Values represent maximal responses. 
109 !
! !
 
Figure 3 Negative chronotropic effects of cumulative doses of propranolol (prop) 
administered intraperitoneally in an adult, male Sprague-Dawley rat. Heart rate (HR) 
at each dose is given as a percent of the steady-state value immediately before that 
dose. Values represent maximal responses. 
 
Figure 4 Positive chronotropic effects of cumulative doses of isoproterenol 
administered intraperitoneally in an adult, male Sprague-Dawley rat. Heart rate (HR) 
at each dose is given as a percent of the steady-state value immediately before that 
dose. Values represent maximal responses. 
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Appendix 2 – Literature used for initial test dose selection  
Table 1. Rationale and references for chosen autonomic receptor drug dosages. 
Drug Dose, route Rationale and references 
Isoproterenol 0.1 mg/kg, i.p. In rats, 0.17 mg/kg isoproterenol was administered 
intraperitoneally, but the resultant change in heart rate was not 
reported (Nomura et al., 1982). In mice, 1.0 mg/kg (i.p.) 
isoproterenol increased heart rates by 50-60% (Petric et al., 2012), 
which is too high for the purposes of this study.  
 
Doses of 0.01 and 0.1 mg/kg i.p. were tested in pilot studies in a 
single rat (Figure 4); 0.1 mg/kg most reliably produced a heart rate 
increase of 20-40% within 3 minutes of injection that lasted at least 
20 minutes. The 0.1 mg/kg dose resulted in heart rates as high as 
550 bpm (which is too rapid to permit cardiac pacing at drive train 
cycle lengths of both 150 and 100 ms).  
 
Propranolol 10 mg/kg, i.p. 10 mg/kg propranolol administered intraperitoneally was an 
effective β-blocker in mice (Argawai and Bose, 1967) while doses 
as high as 50 mg/kg (i.p.) have been used in similar studies of rats 
(Lima and Sourkes, 1986). In another study, 10 mg/kg propranolol 
(i.p.) was administered to rats but the resultant change in heart 
rate was not reported (Nomura et al., 1982).  
 
In pilot studies, cumulative propranolol doses of 1.0, 5.0 and 10 
mg/kg (i.p.) were administered to a single rat (Figure 3). 
 
Carbachol 0.05 mg/kg, i.p. The carbachol dose of 0.05 mg/kg (i.p.) was used for intracardiac 
EP studies in mice (Tuomi et al., 2011, Wakimoto et al., 2001). 
Wakimoto et al. ascertained pharmacokinetics and dose-response 
relationships of i.v. and i.p. carbachol (Wakimoto et al., 2001). 
They found that i.v. carbachol had a low therapeutic index with 
unfavourable effective/lethal dose ratio while i.p. carbachol was 
safe and clearly able to induce a change in heart rate with stable 
hemodynamic conditions.  
 
An ascending dose-response curve (Figure 1) was generated with 
doses ranging from 0.001-0.5 mg/kg i.p. in a single rat;  0.05 mg/kg 
produced heart rate reductions of 16%. 
 
Atropine 1.0 mg/kg, i.p. The atropine dose of 1.0 mg/kg i.p. has been used to increase 
AERPs by roughly 30% in mice (Tuomi et al., 2010) and similar 
LD50 values have been reported for rats (280 mg/kg i.p.; Cahen 
and Tvede, 1952) and mice (250 mg/kg i.p.; Cahen and Tvede, 
1952).   
 
In pilot studies, 1.0 mg/kg (i.p.) atropine increased the HR by 20% 
(Figure 2). 
 
Darifenacin 1.0 mg/kg, i.v. 1.0 mg/kg darifenacin was administered intravenously to reduce 
AERP by about 20% in mice (Tuomi et al., 2010). 
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